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Abstract 
Introduction 
Antibiotic resistance has become a major issue across the globe and the situation is worsening in 
low- and middle-income countries. In sub-Saharan Africa and the world at large, antibiotic 
resistance research is localized and focused on hospitalized individuals. There is, therefore, little 
or no data on antibiotic resistance in the community; especially in children. This study described 
the carriage of resistant isolates in children in Cape Town and investigated the effects of 
antibiotic exposure on the development of resistance in stool using an in-vitro model. 
Materials and Methods 
Stool samples from fifty participants of the Tuberculosis Child Multidrug-resistant Preventive 
Therapy Trial (TB-CHAMP) were cultured onto McConkey agar (MCC) with the addition of 
ertapenem and cefpodoxime discs to select for carbapenem and cephalosporin-resistant and 
susceptible E. coli and Klebsiella isolates. Antibiotic susceptibility testing was performed using 
Kirby Bauer disk diffusion. Carbapenem-, quinolone- and cephalosporin-resistance genes were 
detected by PCR and resistance-conferring mutations were detected using Sanger sequencing. 
Ten stool samples were exposed to two sub-clinical concentrations of amoxicillin, ciprofloxacin 
and colistin for 48 hours, whereafter they were plated onto MCC with the addition of various 
antibiotic discs (amoxicillin, ertapenem, ciprofloxacin, colistin, cefotaxime and nalidixic acid). 
The impact of antibiotic exposure on the development of resistance was assessed by enumeration 
of presumptive resistant E. coli and Klebsiella colonies within the zones of inhibition around the 
antibiotic discs.   
Results 
Twenty-one (42%) of the participants were colonized by quinolone-resistant isolates and 18 
(36%) by cephalosporin-resistant isolates (predicted ESBL-producing organisms). Of the 21 
quinolone-resistant E. coli isolates, 5 (24%) harbored qnrS while of the 6 quinolone-resistant 
Klebsiella isolates, 4 (67%) had qnrB. The most common quinolone resistance mutations were 
S83L in gyrA and S80I, A141V and S129A in parC. blaCTX-M was the only ESBL gene 
detected. All of the blaSHV and blaTEM genes detected were β-lactamases without extended 
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spectrum activity. One of the participants was colonized by a carbapenem resistant Klebsiella 
isolate, which carried the blaNDM carbapenemase gene. 
Exposure of the stool samples to ciprofloxacin selected for resistant bacteria, however exposure 
to amoxicillin and colistin did not.  
Conclusion 
Children in Cape Town are frequently colonized by resistant bacteria and are at risk of becoming 
infected by these resistant organisms. The presence of plasmid-mediated resistance genes is 
concerning because they can be transferred between bacteria of the same and different species. 
There is also a need to further investigate what might be driving the high prevalence of 
quinolone resistance in the community. This study is the first to report the carriage of 
carbapenemase resistant bacteria in healthy children in South Africa. 
Although the in-vitro antibiotic exposure model was crude, the approach provides some evidence 
for the development of resistance during exposure to sub-clinical concentrations of antibiotics 
(especially ciprofloxacin); and notably, to agents other than those to which the sample had been 
exposed. This highlights the need for further investigations into the impact of sublethal antibiotic 
concentrations on the selection of resistance. 
Stellenbosch University https://scholar.sun.ac.za
iv 
 
Opsomming 
Inleiding 
Antibiotiese weerstand is ‘n wêreldwye probleem, en die situasie is besig om in lae- en 
middelvlakinkomstelande te versleg. In sub-Sahara Afrika, en ook die res van die wêreld, fokus 
navorsing oor antibiotiese weerstand grootliks op gehospitaliseerde individue en is meestal 
gelokaliseerd. Daar is dus min tot geen data oor antibiotiese weerstand in die gemeenskap nie; 
veral in kinders. Hierdie studie beskryf die verspreiding van weerstandbiedende bakteriële isolate 
in Kaapstad en het die effek van antibiotika-blootstelling op ontwikkeling van weerstand in 
stoelmonsters met ‘n in-vitro model ondersoek. 
 
Metodes 
Stoelmonsters vanaf vyftig deelnemers van die “Tuberculosis Child Multidrug-resistant 
Preventive Therapy Trial” (TB-CHAMP) is op McConkey agar (MCC) met ertapenem en 
cefpodoksiem skyfies geweek, om karbapenem- en kefalosporien-weerstandbiendende 
en -vatbare E. coli en Klebsiella isolate te selekteer. Antibiotiese vatbaarheidstoetse is deur 
Kirby Bauer skyfiediffusie uitgevoer. Karbapenem, kinoloon en kefalosporien-
weerstandsgewende mutaties is met Sanger DNA-volgordebepaling bespeur. 
Tien stoelmonsters was vir 48 uur aan twee subkliniese konsentrasies van amoksisillien, 
siprofloksasien en colistin blootgestel, waarna hulle op MCC gekweek is met verskeie 
antibiotika skyfies (amoksisillien, ertapenem, siprofloksasien, colistin, kefotaksiem en 
nalidiksiensuur). Escherichia coli en Klebsiella kolonies binne die inhibisie-zones rondom die 
antibiotika skyfies is getel om die impak van antibiotika-blootstelling op die ontwikkeling van 
weerstand te bepaal. 
 
Resultate 
Een-en-twintig (42%) van die deelnemers was met kinoloon-weerstandige isolate gekoloniseer 
en 18 (36%) deur kefalosporien-weerstandige isolate (voorspel om “Extended spectrum beta-
lactamase”-produserend (ESBL) te wees). Van die 21 kinoloon-weerstandige E. coli isolate, het 
5 (24%) qnrS gene besit, terwyl 4 (67%) van die kinoloon-weerstandige Klebsiella isolate 
positief getoets het vir qnrB. Die algemeenste kinoloon weerstandgewende mutaties was S83L in 
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gyrA en S80I, A141V en S129A in parC. blaCTX-M was die algemeenste ESBL geen wat 
geïdentifiseer is. Geen van die geïdentifiseerde blaSHV en blaTEM gene was ESBL-
produserend nie. Een deelnemer was met ‘n karbapenem-weerstandbiedende Klebsiella isolaat 
met ‘n blaNDM karbapenemase geen gekoloniseer.  
In die stoelmonsters het blootstelling aan siprofloksasien, eerder as amoksisillien en colistin, vir 
weerstanbiedende bakterieë geselekteer. 
Gevolgtrekking 
Kinders in Kaapstad word gereeld deur weerstandbiedende bakterieë gekoloniseer en beloop die 
risiko om deur hierdie organismes geïnfekteer te word. Die teenwoordigheid van plasmied-
bemiddelde weerstandsgene is daarom kommerwekkend, aangesien hulle tussen bakterieë van 
dieselfde en verskillende spesies oorgedra kan word. Dit is dus nodig om verdere ondersoek te 
doen om te bepaal wat die hoë vlak van kinoloon-weerstand in die gemeenskap veroorsaak. 
Hierdie studie bevat die eerste beskrywing van die verspreiding van karbapenem 
weerstandbiedende bakterieë in gesonde kinders in Suid-Afrika.  
Alhoewel die in-vitro antibiotika-blootstelling model nie gesofistikeerd was nie, het hierdie 
benadering bewys gegee van die ontwikkeling van weerstand tydens blootstelling aan 
subkliniese konsentrasies van antibiotika (veral siprofloksasien); merkwaardig ook aan ander 
middels waaraan die monsters nie blootgestel was nie. Dit wys dat verdere ondersoek ingestel 
moet word om die impak van subkliniese antibiotika konsentrasies op die seleksie van weerstand 
te bepaal.   
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 : Literature Review Chapter 1
1.1 The Global Problem of Antibiotic Resistance 
The discovery of antibiotics in the early 1930s was considered the beginning of a “golden age” in 
the history of medical practice. Antibiotics made a significant impact on public health, allowing 
infections to be more easily treated and resulting in lives being saved (Grundmann, 2014; Lee et 
al., 2013; Smith & Read, 2016). Nonetheless, this “golden age” is soon to end, since the 21st 
century has encountered antibiotic resistance, and society is now faced with what is being 
referred to as a return to the “pre-antibiotic era”, where antibiotic use is less effective. The 
reduced efficacy of antibiotics has become a threat not only in nosocomial settings but also in the 
community. The issue of antibiotic resistance does not affect only patients but also politicians, 
health insurance companies and global health donors, all of whom play a key role in global 
health (Grundmann, 2014). The anticipation that a novel antibiotic will be discovered to combat 
antibiotic resistance is diminishing, especially for Gram-negative bacteria (Lee, Cho, Jeong & 
Lee, 2013). 
 
In 2013, the Centers for  Disease Control and Prevention (CDC) released a list of the top 18 
antibiotic-resistant microorganisms which require serious attention; this included carbapenem-
resistant Enterobacteriaceae (CRE) and extended spectrum β-lactamase (ESBL) producing 
Enterobacteriaceae (CDC, 2013). European CDC reports identify 3
rd
 generation cephalosporin 
resistance and multidrug resistance to be frequent in Escherichia coli and Klebsiella pneumoniae 
(ECDC, 2015).  
 
The 2013 CDC report shows that in the United States (US) alone, 2 million individuals acquire 
antibiotic-resistant infections annually with 23 000 deaths as a result (CDC, 2013). The US 
spends $21 000-$34 000 million per year on resistance while Europe spends €1 500 million per 
year (Roca et al., 2015). Generally, the prevalence and growth rate of antibiotic resistance is 
17% and 7% respectively in the US (Zhang et al., 2006). Without any global action to mitigate 
and fight antibiotic resistance, there would be 10 million deaths across the globe annually due to 
antibiotic resistance infections by 2050. This means that the world will generate approximately 8 
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trillion United States Dollar (USD) less each year by 2050 and the world will lose 100 trillion 
USD within the next 35 years (O’Neill, 2016). 
 
There are several factors that drive the production of resistance, including the increase in ESBLs 
in Enterobacteriaceae, but high intake of antibiotics is a major factor (Storberg, 2014). Antibiotic 
consumption has increased significantly in Brazil, Russia, India, China, South Africa (BRICS) 
countries, and a similar increase was observed in West Africa. Seventy-six percent of the total 
increase in global antibiotic consumption from 2000-2010 was associated with BRICS countries. 
However, only 33% of the total increase in the world’s population occurred in BRICS countries 
between those years. In BRICS countries, 23% of the increase in the retail sales volume was 
associated with India and 57% of the increase in clinical settings was in China (Van Boeckel et 
al., 2014). Over 90% of antibiotics used in clinical settings in Europe are prescribed to 
outpatients (Bell et al., 2014).  
 
1.2 Gram-Negative Bacteria (GNB) and Infections 
The Enterobacteriaceae is a family of Gram-negative bacilli that can cause both nosocomial and 
community-acquired (CA) infections. Of the Enterobacteriaceae, E. coli and K. pneumoniae are 
among the most commonly isolated pathogens (Iredell et al., 2016).  
 
While E. coli is a common enteric commensal, it is also the most frequently isolated Gram-
negative bacterium in clinical samples and has the ability to cause a range of clinical infections, 
such as pyelonephritis and gastroenteritis (Rezazadeh et al., 2016). E. coli is the commonest 
cause of urinary tract infections (UTI), and it has been estimated that approximately 150 million 
individuals across the globe acquire UTIs annually (Fasugba et al., 2015). E. coli is the leading 
cause of acute diarrhea in most developing countries and it is also associated with enteritis in 
children less than 5 years (Bii et al., 2005). Bloodstream infections (BSI) are the most common 
hospital-acquired (HA) infection caused by E. coli (Chmielarczyk et al., 2015). Thirty-two 
percent of bacteremias due to E. coli in Auckland (Williamson et al., 2013), Canada (Laupland et 
al., 2008) and Minnesota (Al-Hasan et al., 2009) were health-care associated.  
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K. pneumoniae is an opportunistic pathogen associated with both nosocomial and community-
acquired infections (Chung, 2016). K. pneumoniae has the ability to cause several infections 
including bloodstream infections, pneumonia, skin structure infections and UTIs (Cprek & 
Gallagher, 2015). In addition, K. pneumoniae can also cause septicemia, liver abscesses and 
meningitis (Decré et al., 2011).  Epidemiological studies have shown that colonization of the 
gastrointestinal tract (GIT) occurs prior to most K. pneumoniae infections (Struve & Krogfelt, 
2004). From 1996-1997 in the USA, 68 cases of CA bloodstream infections were reported in two 
hospitals and 43% were due to K. pneumoniae. Forty out of 116 cases of CA bloodstream 
infections in Johannesburg, South Africa were due to K. pneumoniae (Ko et al., 2002). Of 864 
cases of pediatric BSI reported in Cape Town of which 404 were HA and 460 CA , nearly 18% 
were due to K. pneumoniae from 2008-2013 (Dramowski et al., 2015).  
 
1.3 Antibiotics and Resistance Mechanisms in Enterobacteriaceae 
Infections with Enterobacteriaceae can be treated using a range of antibiotics (Penesyan et al., 
2015). Different classes have different mechanisms of action, as illustrated in Figure 1.1. Third 
generation cephalosporins, aminoglycosides, polymyxins and fluoroquinolones (ciprofloxacin 
and levofloxacin) have proved to be efficacious against Enterobacteriaceae infections.  
 
Stellenbosch University https://scholar.sun.ac.za
4 
 
 
Figure 1.1. Various classes of antibiotics and their modes of action.  The target site of 
antibiotics depends on their class. (1) Fluoroquinolones target DNA and RNA synthesis (2) β-
lactams target the bacterium cell wall.  
(Adapted from:https://upload.wikimedia.org/wikipedia/commons/6/61/Antibiotic_resistance_mechanisms.jpg) 
 
The increase and inappropriate use of antibiotics has selected mutant bacteria which develop 
resistance to antibiotics (Penesyan et al., 2015). In recent years Enterobacteriaceae have been 
observed to be resistant to third-generation cephalosporins, carbapenems, aminoglycosides, 
polymyxins, and fluoroquinolones (Kocsis and Szabó, 2013). The focus of this research project 
is on resistance to β-lactams and fluoroquinolones, and the following sections will describe the 
mechanisms of action and resistance to these agents in more detail. 
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1.4 β-lactams and β-lactamases 
β-lactam antibiotics are a commonly used class of antibiotic. They are broad-spectrum 
antimicrobials which include all antibiotics with a β-lactam ring in their molecular structure. 
Examples include penicillins, cephalosporins, monobactams and carbapenems (Lakshmi et al., 
2014). The cephalosporin class of antibiotics includes ceftazidime, cefepime, cefuroxime, 
cefpodoxime, and oxyimino-monobactam (Ghafourian et al., 2014). Cephalosporins are 
relatively broad-spectrum antibiotics, with the more recent generations showing increasing 
activity against Gram-negative organisms. Carbapenems are broad spectrum agents, active 
against a wide range of Gram-positive and Gram-negative bacteria, and include ertapenem, 
imipenem, meropenem and doripenem. β-lactams exert their bactericidal effect because of their 
ability to inhibit penicillin-binding proteins (PBP) and thus inhibit cell wall synthesis (Kong et 
al., 2010).  
 
While resistance to β-lactam antibiotics can arise through a variety of mechanisms (Figure 1.2), 
production of β-lactamases is the most common mechanism used by Enterobacteriaceae to confer 
resistance to these agents. These enzymes inactivate β-lactam antibiotics by hydrolysis; they bind 
to the β-lactam ring of the antibiotic, thereby deactivating the molecule. Examples of β-
lactamases include blaAmpC, ESBLs and carbapenemases (Lakshmi et al., 2014). β-lactamases 
have been classified by Ambler based on peptide sequence analogy and phenotypic 
characteristics (Ambler, 1980), while the Bush classification is based on functional and 
molecular groups (Bush et al., 1995). 
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Figure 1.2: β-lactam resistance mechanisms.   The basic mechanisms of β-lactam resistance in 
Enterobacteriaceae include (1) Enzyme inactivation of β-lactam by hydrolysis; these enzymes 
are either chromosome or plasmid-mediated. (2) Efflux pumps and loss of porins also help the 
bacterium to reduce accumulation of drugs. (Adapted from: Nordmann et al. 2012). 
 
1.4.1 blaAmpC β-lactamase 
According to the Ambler classification of β-lactamases, blaAmpCs are classified in class C, 
while the functional classification scheme of Bush et al puts them in group 1. blaAmpC has a 
serine residue at its active site.  
 
blaAmpC β-lactamases are clinically significant cephalosporinases, which are chromosomally-
mediated in certain genera of the Enterobacteriaceae (Jacoby, 2009). In most Enterobacteriaceae, 
blaAmpC genes are expressed at low-levels and are inducible on exposure to β-lactams. 
Mutations in the blaAmpC regulatory regions can also lead to constitutive hyperproduction of 
the enzyme (Tang et al., 2014). blaAmpC β-lactamases hydrolyze both narrow and broad-
spectrum cephalosporins (Marsik & Nambiar, 2011). blaAmpC has been reported all over Africa 
in both community and hospital acquired infections (Storberg, 2014). blaAmpC was always 
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known to be chromosomally-mediated, however recently plasmid-mediated blaAmpC has been 
reported but is less common (Tanushree Barua et al. 2013) 
 
1.4.2 Extended-spectrum β-lactamases (ESBLs) 
Extended-spectrum β-lactamases are enzymes capable of hydrolyzing narrow and broad-
spectrum cephalosporins. ESBLs most often are not active against carbapenems (Paterson & 
Bonomo, 2005). The commonest types of ESBL are those in the blaTEM-, blaSHV-, and 
blaCTX-M families (Kocsis & Szabó, 2013). 
 
1.4.2.1  blaTEM β-lactamase 
blaTEM β-lactamases are categorized by Bush et al under the functional group 2b while 
Ambler’s classification lists them as class A β-lactamases (Ambler, 1980; Bush et al., 1995). 
blaTEM enzymes were originally isolated from Enterobacteriaceae (Monstein et al. 2007) and 
were first reported in Greece in an E. coli isolate (Zaniani et al. 2012). The first plasmid-
mediated blaTEM appeared in the 1960s (Chong, 2011). 
 
More than 130 blaTEM-types are known, but not all have extended-spectrum β-lactamase 
activity (Chong, 2011). blaTEM-1, blaTEM-2, and blaTEM-13 are narrow spectrum  
β-lactamases, not considered ESBLs (Paterson & Bonomo, 2005). blaTEM-1 and blaTEM-2 are 
progenitors, while blaTEMs with extended spectrum activity have a range of amino acid 
substitutions (Jacoby & Munoz-price, 2005). Most blaTEM ESBLs have a single amino acid 
substitution at their active site; this occurs most commonly at positions 104, 164, 238, and 240 
(Jacoby & Munoz-price, 2005). blaTEM genes are plasmid-mediated. 
 
Novel blaTEM β-lactamases have been isolated that are able to hydrolyze third-generation 
cephalosporins and show resistance to β-lactamase inhibitors. These blaTEM β-lactamases are 
also known as inhibitor resistant β-lactamases because they can reduce the susceptibility of 
organisms to clavulanic acid, sulbactam, and tazobactam combinations (Jacoby & Munoz-price, 
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2005; Paterson & Bonomo, 2005). The main producer of blaTEM is E. coli (Jacoby & Munoz-
price, 2005). 
 
1.4.2.2  blaSHV β-lactamase 
Extended-spectrum blaSHV β-lactamases belong to functional group 2be and have also been 
allocated to subclass A1 of serine β-lactamases (Liakopoulos et al., 2016). Not all blaSHVs have 
extended spectrum activity; blaSHV-1, blaSHV-11, and blaSHV-26 lack extended spectrum 
activity (Jiang et al., 2012). The plasmid-mediated blaSHV β-lactamases are derived from a 
chromosomal blaSHV-1 “parent” which is predominantly present in K. pneumoniae. blaSHV-1 
shares 68% of its amino acids with blaTEM-1 and they have a similar structure (Jacoby & 
Munoz-price, 2005). blaSHV β-lactamases with extended spectrum activity also have amino acid 
substitutions at their active site, usually at positions 238 or 240 (Castanheira et al., 2013). An 
blaSHV ESBL was first identified in E. coli in the 1970s (Liakopoulos et al., 2016) and in  
K. pneumoniae in the 1980s. More than 50 blaSHV-types are currently known (Chong, 2011). 
One worth noting is blaSHV-27, which has been identified on different plasmids in E. coli and  
K. pneumoniae.  (Chong, 2011).  
 
blaSHV has been found outside of the normal clinical hosts E. coli and K. pneumoniae and has 
been reported in other Enterobacteriaceae (Liakopoulos et al. 2016). Horizontal gene transfer of 
plasmid-mediated blaSHV between non-related species has also been documented (Garza-
Ramos et al., 2007). Some of the blaSHV variants co-exist with other resistance genes such as 
blaCTX-M and blaVIM (Liakopoulos et al. 2016).  
 
Enterobacteriaceae producing blaSHV ESBLs are mostly resistant to oxyimino β-lactams 
(cefotaxime, ceftazidime) and monobactams (aztreonam) but may be susceptible to carbapenems 
and can be inhibited by β-lactamase inhibitors (Venezia et al., 1995).   
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1.4.2.3  blaCTX-M β-lactamase 
The blaCTX-M β-lactamases got their name from “cefotaximase” activity, which is a distinctive 
characteristic of these enzymes. This unique ability is attributed to a mobile electrostatic feature 
which enables them to track cefotaxime to their binding sites and hydrolyze it (Cantón & Coque, 
2006). blaCTX-M was first detected in Germany and Argentina in 1989, and since then has 
disseminated worldwide. There are different clones of blaCTX-M, the most prevalent include 
blaCTX-M-9, blaCTX-M-14, and blaCTX-M-15. blaCTX-M is prevalent in both hospitals and 
community settings (Bauernfeind et al., 1990; Cantón & Coque, 2006). 
 
blaCTX-M results in a higher level of resistance towards cefotaxime, which is usually observed 
in all bla CTX-M producing isolates (Cantón & Coque, 2006). Carbapenems are stable against 
blaCTX-M-type enzymes; however, when they are hyperproduced and combined with decreased 
outer membrane permeability, blaCTX-M can result in resistance to carbapenems (D’Andrea et 
al., 2013). The phenotypic cross-resistance of ESBL producing Enterobacteriaceae is associated 
with the existence of other genes, normally present in the same plasmid as the blaCTX-M gene. 
Most CTX-M producing organisms are resistant to fluoroquinolones (Cantón & Coque, 2006).  
 
1.4.2.4  Epidemiology of ESBLs 
ESBL-producing Enterobacteriaceae have been reported worldwide (Bevan et al., 2017; Flokas 
et al., 2017; Leopold et al., 2014). According to the European Antibiotic Resistance Surveillance 
Network (EARS-NET) in 2013, 17 out of 22 countries in Europe recorded that 85 to 100% of  
E. coli isolates were ESBL-positive (EARS-Net, 2014). In Latin America in 2014, resistance to 
third-generation cephalosporins among K. pneumoniae ranged from 19%-87% (CDDEP., 2015). 
The International Network for Optimal Resistance Monitoring (INFORM) documented a 12% 
increase in ESBL-producing isolates in US hospitals from 2011 to 2013 (McDanel et al., 2017). 
Fourteen percent of healthy individuals have been reported to be colonized with ESBL-positive 
isolates globally, with 2% prevalence rate in the USA (Karanika et al., 2016). Thirty-five percent 
of E. coli isolates causing urinary tract infections (UTI) were classified phenotypically as  
ESBL-producers from 2009-2010 in Asia-Pacific regions (Hsueh et al., 2011; Lu et al., 2012). 
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The latest report from SMART (Study for Monitoring Antimicrobial Resistance Trends) revealed 
that ESBL-producing E. coli isolates from intra-abdominal infections in the Asia-Pacific region 
almost doubled between 2002-2010, to 40.8%. The rise of ESBL-producing bacteria has made 
the treatment of Enterobacteriaceae in the Asia-Pacific region very difficult (Lee et al., 2013).  
K. pneumoniae used to be recognized as the main carrier of ESBLs in nosocomial infections, but 
in recent years E. coli has become the major source of ESBLs, with a high rate in community 
settings (Cantón & Coque, 2006). The prevalence of community-acquired bloodstream infections 
due to ESBL-producing K. pneumoniae and E. coli have been reported as 55.5% and 16.5% 
respectively in China (Quan et al., 2017). 
 
In Africa, research on antibiotic resistance is localized in various countries but there is no 
research summary of the prevalence of resistance and the genes involved in Enterobacteriaceae 
(Storberg, 2014). Much of the data on antibiotic resistance in Enterobacteriaceae is from 
hospitals, and there is limited or no information on resistance in community-acquired infections 
(Ruppé et al., 2009). In sub-Saharan Africa, resistance to the third-generation cephalosporins 
among Enterobacteriaceae in patients with community-acquired febrile illness was between  
0-47% from 1990-2013 (Leopold et al., 2014). The ESBL prevalence in North Africa ranged 
from 12-99% in hospitals and 1-11% in communities (Khalaf et al., 2009; Naas et al., 2011). In 
East Africa, ESBL producing organisms were found in 38-63% of samples from hospitals and 
6% of community samples (Beyene et al., 2011; Kiiru et al., 2012). The number of deaths due to 
pediatric sepsis caused by ESBL-producers is significantly higher than non-ESBL-producers; in 
tertiary hospitals in Tanzania children less than 8 years with sepsis due to an ESBL-producer had 
a mortality rate of 71% compared to 39% in those with non-ESBL producing organisms 
(Blomberg et al., 2005; Lee et al., 2013).  In some parts of Central Africa, ESBL rates in 
hospital-acquired isolates were as high as 83%, with 17% in community samples (Lonchel et al., 
2012, 2013). ESBL resistance continues to increase in West Africa; at 40% in community and 
63% in the hospitals (Feglo et al., 2013; Tandé et al., 2009) and 49.3% of Enterobacteriaceae 
isolates from Ghanaian hospital has also been identified as ESBL-producing (Obeng-Nkrumah et 
al., 2015). 
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SENTRY antimicrobial surveillance in South Africa revealed that 36% of K. pneumoniae and 
5% of E. coli were ESBL-positive from 1998 to 1999. Similarly, results of the Pan-European 
Antimicrobial Resistance using Local Surveillance (PEARLS) study from 2001 to 2002 in South 
Africa revealed that 34% of K. pneumoniae and 4.6% of E. coli were ESBL-producers 
(Bouchillon et al., 2004). Sixty-two percent of K. pneumoniae isolates from seven government 
hospitals in South Africa were ESBL-producers in 2007 (Bamford et al., 2009). The prevalence 
of  ESBL-producing Enterobacteriaceae in South Africa was 9-13% in hospital and 0.3-5% in 
communities while resistance to third-generation cephalosporins in E. coli and K. pneumoniae 
remained stable at 19% and 32% respectively from 2012 to 2014 (CDDEP, 2015). However, 
within the same period, Vasaikar and colleagues reported an increased prevalence of ESBLs in 
different provinces of South Africa, ranging from 36.1% to 68.3% (Vasaikar et al., 2017).  
 
blaSHV-2 has been reported in South Africa and Laos as the most prevalent blaSHV among  
E. coli isolates (Stoesser et al., 2014; Storberg, 2014). However, a few blaSHV variants such 
blaSHV-30, blaSHV-23, blaSHV-12, and blaSHV-5 have also been documented (Liakopoulos et 
al., 2016; Peirano et al., 2011; Szabó et al., 2005; Usha et al., 2008). Three percent of ESBL 
producers in the fecal carriage of  Cameroonian children in the community were blaSHV-12 
(Lonchel et al., 2012). blaTEM-1 is the most prevalent blaTEM among Enterobacteriaceae in 
South Africa in community and hospital settings (Storberg, 2014) 
 
The first blaCTX-M gene was reported in South Africa in 2006 in a K. pneumoniae isolate 
(Elliott et al., 2006). The blaCTX-M-15 gene has since also been reported in Durban and 
Pretoria ( Usha et al., 2008, Ehlers et al., 2009). Ninety-five percent of ESBL-producing E. coli 
isolates from community hospitals in Cape Town expressed blaCTX-M genes, of which 
blaCTX-M-15 and blaCTX-M-14 were the most prevalent (Peirano et al., 2011). A recent study 
conducted in Mthatha in the Eastern Cape of South Africa showed that 56.7% of clinical 
Klebsiella isolates harbor blaCTX-M (Vasaikar et al., 2017). In Mali, Tunisia, and Cameroon the 
prevalence of blaCTX-M-15 among ESBL producers was 83%, 91%, and 96% respectively 
(Ouedraogo et al., 2016). The global spread of blaCTX-M might be due to the combination of 
mobile genetics and specific clonal dissemination (Ouedraogo et al., 2016). 
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The increasing prevalence of blaCTX-M in hospitals might be due to the introduction of these 
enzymes from the community rather than expansion in the hospitals as documented by previous 
studies (Overdevest et al., 2011). Overdevest and colleagues found ESBL-producing 
Enterobacteriaceae in rectal swabs of 4% of patients before admission to hospital (Overdevest et 
al., 2011). Valverde and colleagues reported that the fecal carriage rate of ESBL producing 
Enterobacteriaceae in a Spanish community was 5.5% in hospitalized and 3.7% in healthy 
individuals in 2003 (Valverde et al., 2004). Fecal carriage of blaCTX-M-producing 
Enterobacteriaceae has been observed in community settings in Asia, America and Europe 
(D’Andrea et al., 2013). A community study in Phnom-Penh, Cambodia, revealed that all  
ESBL-producing isolates carried blaCTX-M (Ruppé et al., 2009). There have also been cases of 
spread of blaCTX-M producers among household contacts (D’Andrea et al., 2013). These 
findings are suggestive evidence that the community might be serving as a reservoir for  
blaCTX-M-producers (D’Andrea et al., 2013) which may have originated in nosocomial settings 
and become established in the community. The danger of blaCTX-M carriage in the community 
is still unexplored (Ruppé et al., 2009). 
 
1.4.3  Carbapenemases 
Carbapenemases have a wide hydrolytic spectrum and are capable of inactivating almost all  
β-lactams. There is a wide range of carbapenemases, and they are not all structurally related. The 
most dominant carbapenemase globally is blaKPC, however recently others such as blaNDM, 
blaIMP, blaVIM, blaGES, and blaOXA-48 have also been reported (Kocsis and Szabó, 2013). 
All the above-mentioned carbapenemases have been reported to occur on plasmids. In South 
Africa, the most prevalent carbapenemases are blaOXA-48 and blaNDM (Osei Sekyere, 2016). 
The main reservoir of Carbapenemase-Producing Enterobacteriaceae (CPE) is the intestinal tract, 
and fecal specimens are used to screen for CPE. It can be difficult to isolate CPE from stool 
samples because they form only a small proportion of the fecal microbial load (Yamamoto et al., 
2017). 
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1.4.3.1  Guiana-Extended-Spectrum Carbapenemase (blaGES) 
blaGES-type enzymes are members of the Ambler class A plasmid-mediated β-lactamases. 
Although blaGES enzymes result in a phenotype similar to ESBLs, they have greater activity 
against carbapenems due to changes in their active site. The blaGES-type has 26 variants and 
they differ from each other by 1 to 4 amino acid substitutions (Frase et al., 2009). blaGES-2, 
blaGES-4, blaGES-5, blaGES-11, blaGES-18, blaGES-20 have disseminated worldwide, with 
reports from Brazil, France and South Africa (Ribeiro et al., 2014). Isolates producing blaGES 
enzymes have been isolated predominantly in Europe, South Africa and the Far East (Walther-
Rasmussen & Høiby, 2007).  
 
1.4.3.2  Klebsiella pneumoniae Carbapenemase (blaKPC) 
blaKPC belongs to the molecular class A serine β-lactamases and functional group 2f (Wolter et 
al., 2009). blaKPC-1-8 have been described (Lee & Burgess 2012) and  South Africa was the 
first country on the African continent to report the presence of blaKPC (Brink et al., 2012). 
blaKPC-producing organisms do not always show phenotypic resistance to carbapenems and 
may resemble ESBL producers (Wolter et al., 2009). However, most hospital-acquired infections 
involving blaKPC are associated with therapeutic failure and a 50% mortality rate (Lee & 
Burgess 2012).  
 
1.4.3.3 New Delhi Metallo- β-lactamase (blaNDM) 
blaNDM is a class B Metallo- β-lactamase, which was first reported in 2008 and is the most 
recently recognized carbapenemase. blaNDM is predominantly found in E. coli and  
K. pneumoniae (Nordmann et al., 2011). In the past years, 17 new variants of blaNDM have 
been reported with one or two amino acid substitutions. Studies to date only report plasmid-
mediated blaNDM genes, especially in Enterobacteriaceae. blaNDM-positive isolates have been 
reported in over 40 countries across the globe. Cases of blaNDM-positive isolates have been 
reported on the African continent from a range of countries, including Algeria and Cameroon, 
with patients transferred from blaNDM endemic areas (Johnson & Woodford, 2013). However, 
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local dissemination of NDM has also been reported in South Africa (Brink et al., 2012) and 
Kenya (Poirel et al., 2011).  
 
1.4.3.4 Imipinim-resistant Metallo-β-lactamase (blaIMP) 
blaIMP is an Ambler subclass B1 metallo-β-lactamase that has developed activity against all β-
lactams except aztreonam (Limbago et al., 2011). The blaIMP-1 enzyme was first discovered in 
1991 in Japan in Serratia marcescens and since then reports have been documented globally 
especially in Enterobacteriaceae (Liu, Pegg, et al., 2012).  Recently, the IMP metallo β-
lactamase (MBL) has disseminated across the Enterobacteriaceae family, including K. 
pneumoniae and E. coli (Notake et al., 2013). 
 
1.4.3.5 Verona integron-encoded Metallo-β-lactamase (blaVIM) 
blaVIM is a class B carbapenemase first detected in Italy in 1999 (Lauretti et al., 1999).  
blaVIM-type enzymes can be categorized into 3 major classes according to amino acid 
sequences; blaVIM-1, -2 and -7. All other newly discovered blaVIM-types cluster with these 
three major variants, and differ by one or two amino acid substitutions. blaVIM-1 and blaVIM-2 
are globally disseminated variants (Cornaglia et al., 2011).  In 2008, Algeria first reported 
blaVIM-19, which differs from blaVIM-1 and blaVIM-4 by one amino acid substitution, in 
Enterobacteriaceae (Robin et al., 2010). In 2006 blaVIM-4 producing K. pneumoniae isolates 
were detected during a hospital outbreak in a Tunisia, demonstrating a possible spread in North 
Africa (Ktari et al., 2006). In 2013, Morocco reported the first blaVIM-1 in K. pneumoniae 
isolates from a non-hospitalized patient (Barguigua, El otmani, et al., 2013).   
 
1.4.3.6 Oxacillinase β-lactamase (blaOXA-48) 
blaOXA-48 is an Ambler class D β-lactamase. blaOXA-48 like variants have been described all 
over the world, with blaOXA-48 being the most predominant carbapenemase globally and the 
most commonly detected carbapenemase in Enterobacteriaceae. blaOXA-48 was first detected in 
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carbapenem-resistant K. pneumoniae from Istanbul, Turkey in 2001. blaOXA-48 is common in 
North and South Africa, Middle East, Turkey and India, which might serve as reservoirs since 
related clones from these countries have been observed in Europe and other parts of the world 
(Poirel et al., 2012).  
 
1.5.3.7 Epidemiology of Carbapenemases 
Five European countries have reported increases in carbapenemase-producing Enterobacteriaceae 
(CPE) in 2013 (EARS-Net, 2014). In hospitals in the USA in 2013, rates of carbapenem 
resistance in K. pneumoniae and E. coli were 11 and 2% respectively. In India, 13% of E. coli 
isolates were resistant to carbapenems in 2013, and in 2014 57% of K. pneumoniae isolates were 
resistant to carbapenems (Storberg, 2014). 
 
In South Africa, the first blaNDM carbapenemase was reported in 2010 and since then several 
cases have been recorded across the country. blaNDM-producing Enterobacteriaceae are 
becoming endemic, both localized and cases from the foreign countries have been reported 
(Jager et al., 2015; Lowman et al., 2011). Nineteen out of 70 CPE isolates received from public 
and private hospitals in South Africa were blaNDM-positive (Laxminarayan et al., 2013). VIM-1 
producing Enterobacteriaceae have been documented in South Africa  (Jager et al., 2015). In 
2013, the prevalence of carbapenem resistance was 2 and 0.8% in K. pneumoniae and E. coli 
isolates respectively in South Africa (CDDEP., 2015). Although surveillance for CRE in South 
Africa is still based primarily on voluntary submission of isolates, a recent review confirmed 
approximately 2315 cases of CRE from 2000 to 2016, of which 49% were Klebsiella 
pneumoniae (Osei Sekyere, 2016). While carbapenem resistance is most likely to be associated 
with hospital acquired infections, there is little data from South Africa confirming what 
proportion of carbapenem resistant Enterobacteriaceae are hospital acquired. 
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1.5 Fluoroquinolone Resistance in Enterobacteriaceae 
Quinolones are one of the world’s most commonly prescribed antibiotics, and are used to treat 
bacterial infections such as UTI (Aldred et al., 2014). Quinolones target two important enzymes 
in the bacterial cell; DNA gyrase (topoisomerase II) and DNA topoisomerase IV. These enzymes 
are involved in DNA replication and synthesis (Drlica et al., 2009). Nalidixic acid was the first 
quinolone to be introduced in the 1960s (Aldred et al., 2014). Subsequently, the 
fluoroquinolones (such as ciprofloxacin, levofloxacin, and moxifloxacin) were developed and 
introduced, with improved pharmacokinetics, as well as improved activity against Gram-positive 
organisms (Kocsis & Szabó, 2013).  
 
Quinolone resistance can either be chromosomal or plasmid-mediated (Kocsis & Szabó, 2013). 
Mutations in the chromosomal genes encoding the gyrase and topoisomerase enzymes (gyrA/B 
and parC/E) are the commonest mechanisms of resistance. More recently described mechanism 
of resistance involve the plasmid-mediated qnr-family of genes (qnrA, qnrB, qnrC, qnrD, and 
qnrS). The first qnr gene was identified in E. coli, and it mediates resistance by protecting DNA 
gyrase from inhibition by fluoroquinolone antibiotics (Guan et al., 2013).  
 
Enterobacteriaceae can also develop resistance to quinolones through the acquisition of efflux 
pumps. The efflux pumps are made of a membrane fusion protein (AcrA), inner membrane pump 
(AcrB) and an outer membrane protein (ToiC). Hyperproduction of these proteins leads to 
fluoroquinolone resistance by actively exporting the antibiotic from the bacterial cell; as shown 
in Figure 1.3 (Kocsis & Szabó, 2013). Other plasmid-encoded genes which can play a role in 
quinolone resistance are qepA and oqxAB which also produce efflux pumps (Rodriguez-Martinez 
et al., 2016). The enzyme aminoglycoside acetyltransferase aac(6’)-Ib-cr, causes reduced 
susceptibility to aminoglycosides and to some fluoroquinolones. 
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Figure 1.3: Fluoroquinolone resistance mechanisms. (a). Chromosomal mutations in the 
QRDRs genes (gyrA and parC) alter the target site, reducing the binding affinity of the 
antibiotic. (b). Reduced porin expression due to chromosomal mutations (c) QepA and OqxAB 
efflux pumps play a role in quinolone resistance (d) Plasmid-mediated quinolone resistance 
genes (qnrA, qnrB, and qnrS) promote the resistance by protecting DNA gyrase and 
topoisomerase IV from quinolone inhibition. (Adapted from Correia et al. 2017) 
 
1.5.1  Plasmid-mediated Quinolone Resistance 
It is important to note that plasmid-mediated qnr genes by themselves do not confer resistance, 
but promote the selection of microorganisms with higher Minimum Inhibition Concentrations 
(MIC), therefore allowing the acquisition of other resistance mutations (Guan et al., 2013). A 
recent study in Morocco showed that some isolates expressing Plasmid-mediated Quinolone 
Resistance (PMQR) were not resistant to fluoroquinolones while others which have reduced 
susceptibility to fluoroquinolones do not express PMQR (Benaicha et al., 2017).   
 
PMQR genes, such as qepA and qnr, are mostly co-expressed with ESBLs because they are 
usually located on the same genetic elements (Crémet et al., 2011). Fluoroquinolone-resistance 
genes such as qnrA and qnrB have been co-expressed with CTX-M genes. qnrA has been 
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detected in blaCTX-M-9 and blaCTX-M-14 producing isolates; whereas qnrB and aac(60)-Ib-cr 
have been linked with blaCTX-M-15 (Cantón & Coque, 2006).  
 
1.5.1.1 qnrA 
qnrA was the first plasmid-mediated quinolone resistance gene, described in K. pneumoniae, in 
the USA in 1988.  Since then several plasmid-encoded quinolone resistance genes have been 
described including qnrB and qnrS (Qian et al., 2017). The qnrA gene is said to have originated 
from Shewanella algae (Guan et al., 2013), and has also been identified in phages from water 
samples (Rodriguez-Martinez et al., 2016). 
 
When qnrA is co-expressed with acc-(6’)-Ib-cr the level of ciprofloxacin resistance is increased 
4-fold compared to qnrA alone (Vali et al., 2015). qnrA confers resistance to quinolones such as 
nalidixic acid and increases the MIC 20-fold. Conjugation with a qnrA plasmid using E. coli J53 
increased resistance to nalidixic acid between 12.5 and 250-fold (Guan et al., 2013).  
 
1.5.1.2   qnrB 
qnrB was first reported in 1998 and has diversified over the years resulting in many variants 
(Hong et al., 2009). Among all the qnrB variants, qnrB31 and qnrB32 have the highest amino 
acid similarity. Of the qnr genes involved in quinolone resistance, qnrB is most prevalent. qnrB 
confers low-level resistance to quinolones, but also has a unique characteristic which enables it 
to mimic DNA and serve as a substrate for DNA gyrase (Wang et al., 2011).  
 
qnrB has been found to be widely disseminated in South America (Armas-Freire et al., 2015). A 
study in Ecuador by Armas-Freire suggested that qnrB is predominant in rural settings where 
antibiotic use is low compared to urban nosocomial settings (Armas-Freire et al., 2015). Some 
other studies have demonstrated that qnrB is predominant in commensal E. coli that were 
isolated from healthy children in Peru and Bolivia (Pallecchi et al., 2010). A recent study in 
American Crows showed that 25% of their fecal samples contained qnrB (Halová et al., 2014). 
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Reports suggest that there might be a link between plasmid-mediated quinolone resistance and 
extended spectrum β-lactamases, with blaCTX-M-15 and blaSHV-ESBLs located on the same 
plasmid as qnrB (Strahilevitz et al., 2009) 
 
1.5.1.3 qnrS 
qnrS was first reported in Shigella flexneri (Poirel et al., 2006) and has 9 known variants 
(Dobiasova et al., 2015). Two variants of qnrS, i.e. qnrS1 and qnrS2, have been identified which 
have 40% and 59% similarity to qnrA1, respectively (Cattoir et al., 2007).  
 
qnrS is the most frequently isolated plasmid-mediated quinolone resistance gene in K. 
pneumoniae and E. coli in China (Pasom et al., 2013). Four percent of clinical E. coli isolates 
harbored qnrS in China (Jiang et al., 2014). qnrS1 is one of the most common plasmid-mediated 
quinolone resistance mechanisms recently reported in Durban, South Africa (Osei Sekyere & 
Amoako, 2017).  
 
qnrS has been isolated from a number of environmental and agricultural settings, including 
wastewater, aquatic birds and farm animals (Colomer-Lluch et al., 2014; Dobiasova et al., 2015).  
There have been several reports of qnrS-positive isolates co-expressing ESBLs (Strahilevitz et 
al., 2009), and other antibiotic-resistance genes have also been located on the same plasmid as 
qnrS (Dobiasova et al., 2015). blaCTX-M has been detected in qnrS-positive E. coli isolates. 
Among 18 qnrS-positive isolates from pigs in Taiwan, 12 had a confirmed blaCTX-M-1 and 
three had  blaCTX-M-15 (Kuo et al., 2009). This new information adds to the fact that there 
might be a close link between qnrS and blaCTX-M in E. coli isolates, selecting for diverse 
resistance mechanisms in E. coli isolates in farm animals. A clinical E. coli isolate from China 
carried  blaOXA-181 and qnrS1 on the same plasmid (Pulss et al., 2017) and aac(6’)-lb-cr has 
also been linked with qnrS (Ory et al., 2016).  
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1.5.2 Chromosomal Quinolone Resistance Mutations 
The resistance of E. coli isolates to quinolones is often linked to alterations in DNA 
topoisomerase II. Topoisomerase II has two subunits i.e. gyrA and gyrB (Mehla & Ramana, 
2016). Topoisomerase IV consists of two subunits (parC and parE) which are homologous to 
gyrA and gyrB, respectively. A recent study has shown that quinolones interact with 
topoisomerase IV through a water-metal ion bridge, and partial disruption of this bridge, 
resulting from mutation, leads to decreased susceptibility (Aldred et al., 2014).  
GyrA has a distinct characteristic which induces a negative supercoil into DNA, which helps in 
the replication of the DNA (Mehla & Ramana, 2016). GyrA has a tyrosine at its active site which 
is responsible for DNA cleavage and ligation. GyrB has ATPase activity and is necessary for all 
catalytic activities (Aldred et al., 2014).  
 
Chromosomal mutations in gyrA play a significant role in quinolone resistance (Gu et al., 2017). 
Mutations are more often seen in gyrA as compared to parC; and most reported alterations are at 
the serine codon 83, as shown in Table 1.1 (Onseedaeng & Ratthawongjirakul, 2016). This 
mutation is the initial step in acquiring fluoroquinolone resistance and most often results in high-
level nalidixic acid resistance (Abdi-Hachesoo et al., 2013). Asp87 and Ser83 substitutions are 
the most frequently reported in E. coli (Piekarska et al., 2015).  The number of DNA alterations 
in quinolone resistance determination regions of gyrA is significantly linked to MICs of 
quinolones (Liu, Liao, et al., 2012). It has been hypothesized that gyrA appears as a primary 
fluoroquinolone target in Enterobacteriaceae (Piekarska et al., 2015). Mutations in parC are the 
next step leading to high level fluoroquinolone resistance (Liu, Liao, et al., 2012). 
Topoisomerase IV (ParC) is the secondary target of quinolones if mutations in gyrase are present 
(Chenia et al., 2006). Ser80 and Glu84 substitutions in ParC are the most frequently reported 
mutations in E. coli isolates with reduced susceptibility to fluoroquinolones (Piekarska et al., 
2015). Mutations in the quinolone resistance determination region of parC result in high level 
fluoroquinolone resistance (Gu et al., 2017). Many isolates that showed resistance to 
levofloxacin and ciprofloxacin had alterations in ParC i.e. Ser87Leu and Ala88Pro mutations 
(Nouri et al., 2016). A K. pneumoniae isolate with mutations in the parC gene coupled with 
aac(6’)-Ib-cr and qnrB1 was shown to have a ciprofloxacin MIC of 16 mg/L. Mutations in parC 
Stellenbosch University https://scholar.sun.ac.za
21 
 
alone cause higher ciprofloxacin MICs, ranging from 0.125 to 128 mg/l (Liu, Liao, et al., 2012). 
Isolates that have mutations in both gyrA and parC genes have high-level resistance to 
ciprofloxacin and levofloxacin, compared to those with mutations in gyrA alone (Nouri et al., 
2016).  
 
Table 1.1: Frequently reported fluoroquinolone resistance mutations in GyrA and ParC  
GyrA ParC 
Mutations References Mutations References 
S83L (Gu et al. 2017) S80I (Liu et al., 2012) 
S83A (Liu et al., 2012) S80R (Liu et al., 2012) 
S83I (Fu et al., 2013) E84K (Liu et al., 2012) 
S83F (Fu et al., 2013) E84G (Liu et al., 2012) 
S83Y (Fu et al., 2013) E84V (Onseedaeng&Ratthawongjirakul 2016) 
T83I (Nouri et al. 2016) Met86Tp (Gu et al. 2017) 
Al84V (Piekarska et al. 2015) S87L (Nouri et al. 2016) 
D87N/G (Gu et al. 2017) A88P (Nouri et al. 2016) 
D87E (Piekarska et al. 2015) A90V (Onseedaeng&Ratthawongjirakul 2016) 
D87Y 
(Onseedaeng & 
Ratthawongjirakul 2016) 
A108T (Onseedaeng&Ratthawongjirakul 2016) 
D87A (Liu et al., 2012) Al108V (Liu et al., 2012) 
D87H (Liu et al., 2012) S129P (Gu et al. 2017) 
I89F (Liu et al., 2012) S129A (Norouzi et al., 2014) 
K154R (Norouzi et al., 2014) A141V (Norouzi et al., 2014) 
S171A (Norouzi et al., 2014) 
 
V190G (Norouzi et al., 2014) 
H211Y (Gu et al. 2017) 
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1.5.3   Epidemiology of Quinolone Resistance 
From 1997 to 1999 approximately 50% of community and 60% of hospital-acquired E. coli 
isolates in China were resistant to ciprofloxacin (Guan et al., 2013). In Thailand, a study aimed 
at investigating the prevalence of antibiotic resistance in fecal flora of patients undergoing a 
transrectal ultrasound-guided needle biopsy of the prostate (TRUSB) showed that the prevalence 
of fluoroquinolone and cephalosporin-resistant E. coli and K. pneumoniae was high in patients 
who had fluoroquinolone prophylaxis (Siriboon et al., 2012). A study in Paris showed the 
emergence of quinolone resistance in E. coli isolates in 10 of 40 healthy adults exposed to 14 
days of oral ciprofloxacin, although resistance was absent at baseline (Fantin et al., 2009).  
Interestingly, rooks may be a reservoir for the spread of quinolone-resistant bacteria in Europe. A 
recent study in Europe showed the prevalence of ciprofloxacin-resistant Enterobacteriaceae to 
range from 3% to 92% in rooks (Halová et al., 2014). Gurnee et al reported that 20% of children 
and their mothers were colonized by ciprofloxacin-resistant Gram negative bacteria in the USA 
from January, 2010 to May, 2013 (Gurnee et al., 2015).  
 
In Africa, ciprofloxacin-resistant Klebsiella isolates from outpatient departments range  from 0-
47% (Tansarli et al., 2013). In South Africa ciprofloxacin-resistant Enterobacteriaceae ranged 
from 0-15% in public hospitals in 2007, while in 2010, 18% were ciprofloxacin-resistant 
(Bamford et al., 2009, 2011). Sixty percent of Klebsiella isolates from the NHLS laboratory in 
the Eastern Cape of South Africa are ciprofloxacin-resistant (Vasaikar et al., 2017),  whereas it is 
not clear what proportion were from community acquired infections. Although limited, these 
data do suggest that FQ resistance is relatively common, and thus of clinical concern. 
 
1.6 The Effect of Antibiotic Exposure on Selection of Resistance 
There is good evidence that increased consumption of antibiotics drives antibiotic resistance 
(Cantón & Morosini, 2011). Yet it is poorly defined as to whether the same can be expected in 
vitro. Few in vitro studies and animal models have provided knowledge of how resistance 
emerges (Craig, 1998; Sykes, 2010). Previously it was believed that resistance could only 
emerge as a result of exposure to a lethal antibiotic concentration [i.e. concentrations above the 
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organism’s minimum inhibition concentration (MIC) for the particular antibiotic]. The concern 
that sublethal concentrations (below MIC) could select for resistance was nearly ignored 
(Andersson & Hughes, 2014). However, recent studies begin to reveal that low-level antibiotic 
concentration is a major selector of resistant mutants (Andersson & Hughes, 2014). 
 
Exposure of E. coli to ampicillin (1 µg/ml), norfloxacin (15 µg/ml) and kanamycin (3 µg/ml) 
resulted in a significant increase in the proportion of resistant isolates compared to isolates not 
exposed to the antibiotic. The MIC of the isolates selected after ampicillin exposure was 5-fold 
higher than wild-type, while the MICs of kanamycin and norfloxacin were approximately 2 and 
3-fold higher, respectively. Ampicillin exposed isolates were resistant to ampicillin and 
norfloxacin while resistant isolates after norfloxacin and kanamycin exposure were resistant to 
ampicillin (Kohanski et al., 2010). Resistant E. coli selected from media containing a low 
concentration of tetracycline and chloramphenicol were 6-8 fold less susceptible to 
fluoroquinolones (norfloxacin, ofloxacin, ciprofloxacin, and nalidixic acid) than the wild-type 
(Cohen et al., 1989). In another experiment, E. coli and Salmonella typhimurium were exposed 
to ciprofloxacin and streptomycin at 0.1x MIC of their susceptible wild-type; this exposure led to 
increased resistance. After several generations, E. coli had a 2-fold higher MIC than that of the 
wild-type strain after ciprofloxacin exposure.  The MIC of S. typhimurium was 8-fold higher than 
the wild-type strain after being exposed to streptomycin (Gullberg et al., 2011). Resistant E. coli 
isolates selected by exposure to sub-MIC concentrations of oxacillin were also resistant to 
ciprofloxacin and pre-treatment with sub-MIC levels of vancomycin led to gentamicin resistance 
(Johnson & Levin, 2013). These data show that sublethal antibiotic concentrations do not only 
enrich for existing mutants but may also select for de novo resistance in wild-type susceptible 
populations (Gullberg et al., 2011). Exposure to low concentrations of antibiotics can select for 
low-level resistance which can gradually lead to high-level resistance (Baquero, 2001). 
Antibiotic selection enriches the number of resistance genes in a microbial population, but these 
genes might exist before the selection (Cantón & Morosini, 2011). 
 
Antibiotic absorption to different parts of the body is irregular and mostly depends on the 
pharmacodynamics and pharmacokinetics of the antibiotics (Baquero & Negri, 1997). The 
concentration of antibiotic at these sites may be sublethal and is probably more likely to select 
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for resistance; 20-80% of antibiotics are recovered in stool and most of the concentrations of 
antibiotics in stool are sublethal and can select for resistance (Baquero & Negri, 1997; Johnson, 
2006). 
  
It is now clear that selection of resistance to antibiotics can occur not only at high concentrations 
but at a wide range of concentrations. However, it is difficult to define the lowest concentration 
of antibiotics that can still select for resistance. The few studies done on in vitro antibiotic 
exposure have been on selected antibiotics. It is important to investigate this in a wider class of 
antibiotics. The medical significance of acquisition of resistance caused by sub MIC antibiotic 
exposure is under-explored (Andersson & Hughes, 2014). 
 
1.7 Surveillance as a Strategy to Combat Antibiotic Resistance 
Surveillance is one of the key strategies to combat AMR. In May 2015, the WHO adopted a 
global plan which focuses on ensuring that antibiotics are of good quality, effective and available 
to those who need them. It is anticipated that individual countries will develop their own national 
plans on antimicrobial resistance in line with WHO global plan (WHO, 2016).  Few member 
states have regulations on antimicrobials (CDC, 2013).  
The following actions can help monitor and control antimicrobial resistance globally: 
surveillance of antimicrobial resistance and tracking of resistance patterns by DNA sequencing 
(CDC, 2013).  
 
Antibiotic resistance surveillance is needed for several reasons: it enables potential problem 
areas to be identified early and tackled; it is important for any antimicrobial stewardship 
initiative to accomplish its purpose; it is  necessary for monitoring national and regional 
antibiotic consumption and to monitor the antibiotic prescription rate in private and public health 
facilities (Suleman & Meyer, 2012).  
 
Many countries have surveillance systems in place to report and track antibiotic resistance in 
community and hospital-acquired infections, including UK, USA, China, India, Vietnam, New 
Zealand, and South Africa. South Africa presently compiles data from the government and 
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private sectors using laboratory-based surveillance for the ESKAPE organisms (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, Enterobacter spp.). In the government sector, the laboratory data are 
compiled by the National Institute for Communicable Diseases (NICD) and includes data 
gathered from public hospitals by the GERMS-SA network (Group for Enteric, Respiratory and 
Meningeal disease surveillance in South Africa), a nationwide clinical microbiology network. 
Data from the private sector are collected by the South African Society of Clinical Microbiology. 
The South African Society of Clinical Microbiology (SASCM) and the South African Antibiotic 
Stewardship (SAASP) Partnership are compiling these sets of data (CDDEP, 2015). 
 
The 2014 antibiotic resistance surveillance report released by WHO revealed a high rate of 
resistance in pathogens that cause community and nosocomial infections and has also pinpointed 
the absence of population-based AMR surveillance that could provide good information on the 
dissemination, mortality and economic impact on society (WHO, 2014).  
 
It is very difficult to understand the mode of transmission of antibiotic resistance because most 
studies focus on tertiary hospitals and those who consider community enrolment, recruit only a 
small portion of the entire population (Grundmann, 2014).  
 
Information in the above-mentioned areas on surveillance is needed to draft guidelines for public 
health intervention (FAO et al., 2017). The ability to identify and profile novel antibiotic 
resistance mechanisms is necessary to ensure effective surveillance (WHO, 2015).  However, 
detection of antibiotic mechanisms requires specialized skills and equipment; for this reason, 
global antibiotic surveillance cannot be built instantly but requires a guided developmental 
process (Grundmann, 2014). The world currently needs surveillance that produces quality data; 
this is vital for comprehensive global strategies and public health actions to control antibiotic 
resistance (WHO, 2014). 
 
Exposure to antibiotics plays a crucial role in selecting for resistant bacteria. This selective 
pressure is due to the abuse and inappropriate use of antibiotics in patients, farm animals and in 
the environment. The environment has also contributed largely to the spread and transmission of 
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resistance. Major environmental sources include manure from farm animals, wastewater plants 
and hospital sewage. There is a need for policy-makers to devise strategies to minimize the risk 
of environmental exposure. The use of antibiotics for prophylactic treatment in veterinary 
medicine has caused the spread of resistance through the food chain. Interventions to tackle 
antibiotic resistance in animal farming could include improved hygiene in animal houses and 
educating veterinarians and other animal husbandry practitioners. The European Food Authority 
is playing a significant role in identifying risks of antibiotic resistance associated with the food 
industry (Roca et al., 2015).  
 
1.7.1  Limitations to antibiotic resistance surveillance in Africa 
Antibiotic resistance is not only a clinical issue but also a global threat; the WHO and CDC have 
called on all stakeholders to join the fight against antibiotic resistance (Roca et al., 2015). WHO 
recognizes laboratory-based surveillance as a priority for the global containment of antibiotic 
resistance; but for this to be a reality in Africa, state of the art laboratories in various health 
sectors of the continent will be needed, this will also help policymakers to make decisions 
concerning antibiotic resistance (WHO 2001).  
 
A recent study by WHO and the NICD in South Africa revealed weaknesses in the laboratory 
capacity of most African countries and their inability to do valid susceptibility testing. There is a 
lack of proper framework which collaborates and identifies novel antibiotic resistance 
mechanisms and resistance profiles in Africa. This is a limitation to the progress of continental 
surveillance. Continental antibiotic resistance surveillance will help us know the impact of 
interventions in Africa because policymakers are now able to update the antimicrobial resistance 
policy (Ndihokubwayo et al., 2013).  
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1.8 Problem Statement 
There is a lack of information related to carriage of antibiotic resistance and mechanisms of 
resistance in children, and in the community in general; and the impact of antibiotic exposure on 
the development and carriage of resistance is poorly understood.   
 
1.9 Study Design 
The Tuberculosis Child Multidrug-resistant Preventive Therapy Trial (TB-CHAMP) is a phase 
III cluster randomized placebo-controlled trial to evaluate the efficacy of levofloxacin for 
multidrug-resistant (MDR) tuberculosis (TB) prophylaxis in children (<5 years) whose contacts 
have confirmed MDR-TB. This study provides an opportunity to investigate the carriage of 
antibiotic resistance and mechanisms of resistance in children in the community, and to 
investigate the impact of antibiotic exposure on resistance rates. Baseline stool samples were 
collected from children enrolled in TB-CHAMP for surveillance of resistance. 
 
1.10  Aim 
The aims of this study are to describe baseline rates of antibiotic resistance carriage in Gram-
negative organisms in children in the community and to investigate the effects of antibiotic 
exposure on the transfer and acquisition of resistance in stool using an in vitro model. 
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 : Culture-based Screening for Resistant E. coli and Klebsiella spp. Chapter 2
in Stool Samples 
2.1 Introduction 
Most of the current data and research dealing with antimicrobial resistance has been conducted 
on adults. Data on pediatric antimicrobial resistance is lacking, and where data is available, it 
focuses on hospitalized patients (Bryce et al., 2016). There is therefore minimal data on 
antimicrobial resistance in children in a community setting. This is true for South Africa and 
other countries in Africa and it is of much interest. Community-acquired infections are a 
common cause of morbidity and mortality among children, and inappropriate antimicrobial 
choices are associated with worse clinical outcomes. 
 
Efforts to describe rates of antimicrobial resistance in the community have been limited by 
aggregated laboratory data with little or no differentiation between community and hospitalized 
patient, as well as sometimes small sample sizes (Ashley et al., 2011). Various culture-based 
screening methods have been described to identify ESBL producing organisms, using 
ceftazidime or cefpodoxime disks on McConkey agar and CHROMagar ESBL (Gazin et al., 
2012; Huang et al., 2010). All these methods have yielded good results, however in this study we 
compared the use of cefpodoxime disks on McConkey agar to CHROMagar ESBL on a subset of 
isolates in order to identify the most effective, readily available and cheap method. The methods 
employed in this chapter were intended to maximize the chance of isolating ESBL producing E. 
coli and Klebsiella spp isolates, and to provide a representative collection of non-ESBL 
producing isolates both to screen for isolated fluoroquinolone and carbapenem resistance and to 
establish a bank of community-associated susceptible wild-type isolates.  
 
The aim of this chapter is to describe the antibiotic susceptibility profiles of E. coli and 
Klebsiella isolates obtained from stool samples from healthy children in Cape Town. Subsequent 
chapters will describe additional molecular analyses of resistance mechanisms. 
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2.2  Materials and Methods 
2.2.1 Study Population 
This study forms part of a parallel-group, two-arm, cluster-randomized, double-blind placebo-
controlled tuberculosis (TB) prevention trial (TB-CHAMP), which focuses on evaluating the 
efficacy of levofloxacin prophylaxis for MDR-TB (http://www.isrctn.com/ISRCTN92634082). 
Children less than 5 years whose parents or household contacts have confirmed MDR-TB are 
randomized to either 6 months of levofloxacin or 6 months of placebo, in a 1:1 ratio.  
The TB-CHAMP project is being conducted at the Desmond Tutu TB Centre (DTTC), 
Stellenbosch University. The Center has two clinics in Cape Town, South Africa (DTTC Tambo 
Road Clinic and DTTC Beautiful Gate Clinic) where the participants are being enrolled. Tambo 
Road is in Khayelitsha, an informal settlement mostly populated by black Africans. Beautiful 
Gate, Philippi is a farming area which is mostly dominated by “peasant farmers”. While 
participants are drawn from across Cape Town, the majority live in poor, high-density, urban 
areas. 
 
2.2.1.1 Participant Inclusion Criteria 
1. Child <5 years who is a household contact of an enrolled adult MDR-TB index case diagnosed 
during the previous 6 months 
2. Primary residence in the household of the adult MDR-TB index case  
3. Consent from the parent or legal guardian for the child for HIV testing (both HIV-infected and 
uninfected children will be included) 
4. Consent obtained from the parent or legal guardian for the child to be enrolled  
 
2.2.1.2 Child Participant Exclusion Criteria 
1. TB disease at enrolment  
2. Currently on isoniazid (INH) or a fluoroquinolone (FQN) (e.g. levofloxacin, moxifloxacin 
ofloxacin or ciprofloxacin) for ≥14 days  
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3. Treated for TB in the previous 12 months  
4. Known concurrent exposure to an INH-susceptible (including rifampicin-monoresistant) index 
case 
5. Children with myasthenia gravis or Guillain-Barré syndrome  
 
2.2.2   Ethical Consideration 
This study is part of a large research study (TB-CHAMP) for which ethics was approved by the 
Health Research Ethics Committee (HREC) at Stellenbosch University (S17/11/269). Provision 
for the collection of stool samples from participants is included in the TB-CHAMP study 
protocol and the informed consent process for TB-CHAMP. Informed consent was obtained 
from the parent or legal guardian of the participants. All samples and isolates were identified by 
study numbers, and no patient identifiers were captured. All data were maintained on a 
password-protected database, and all paper records were locked away. 
 
2.2.3   Sample Collection 
Prior to the initiation of prophylactic treatment or placebo, baseline samples were collected from 
enrolled children. Stool samples were collected by nurses/counselors per DTTC stool collection 
SOP (Appendix 1), making sure that urine or other environmental samples did not contaminate 
the container. Six scoops of formed stool or 3 scoops of loose stool were collected using a 2.5 ml 
spoon (Lasec, South Africa) and mixed several times for a uniform mixture (only urine-free 
stools were mixed). The stool containers were sealed, and the outside decontaminated with 70% 
ethanol. The containers were placed in a sealable plastic bag and labeled with a Subject Event 
barcode. The nurses/counselors then complete the requisition form (Appendix 2). The samples 
were stored in a fridge at the clinic (2-8°C) until transported to the laboratory.  
 
In cases where stool could not be collected at the clinic by nurses/counselors, verbal instruction 
regarding the method of collection was given to the caregivers by the nurses/counselors together 
with an instruction leaflet (Appendix 3) and the stool collection kit without a requisition form. 
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The stool collection kit included a plastic leakproof screw-cap specimen container with a 2.5 ml 
spoon, leakproof bag, an opaque carrier, labels, a polystyrene cool box, and ice bricks.  
 
The caregivers were encouraged to put the stool sample in the collection container as previously 
described and note the time and date of collection (either the night before or on the morning of       
the clinic visit). The caregivers were also entreated to put the sample on ice bricks in a cool box 
or in the coolest place in the house, until delivered to the clinic or picked up by the driver. 
 
The sample was brought to Division of Medical Microbiology in a cooler box with an ice pack 
(2-8°C) during transport. Upon arrival at the medical microbiology laboratory, a swab of the 
stool was transferred to Cary Blair medium (Diagnostic Media Products, NHLS, South Africa) 
and stored at 4°C. The remaining sample was frozen at -80°C. The maximum time for which the 
samples were stored in Clary Blair before inoculation onto culture media was 7 days. 
 
2.2.4  Bacterial Culture 
Samples were inoculated onto CHROMagar ESBL (Biomerieux, France) for screening for 
ESBL-producing organisms. These agar plates have a reported sensitivity for detection of ESBLs 
of >95% (Gazin et al., 2012); the medium contains a broad-spectrum β-lactam which is intended 
to select for putative 3
rd
 generation cephalosporin-resistant Enterobacteriaceae. The chromogens 
in the medium allow for the differentiation of various species in the family Enterobacteriaceae by 
producing colored colonies specific to each species. Isolates of E. coli and Klebsiella spp. from 
the chromogenic medium were selected for further analysis as detailed below.  
 
Samples were also inoculated onto standard McConkey agar (NHLS Media Laboratory, 
Greenpoint, South Africa) with the addition of a 10 µg cefpodoxime and a 10 µg ertapenem disc 
(Mast, Laboratories, UK). Cefpodoxime is a 3
rd
 generation cephalosporin and ertapenem is a 
carbapenem; isolates within the zone of inhibition were followed up as putative ESBL and/or 
carbapenemase producers respectively. Colonies were presumptively identified as either E. coli 
or Klebsiella spp. based on fermentation of lactose (pink-pigmented colonies) as well as the 
typical colony morphology. Suspected E. coli and Klebsiella spp. isolates growing outside of the 
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zone of inhibition were followed up in an attempt to obtain susceptible isolates. The use of the 
cefpodoxime disc enabled the comparison between the “low cost” screening using discs with the 
more expensive CHROMagar plates.  
All 69 isolates (whether from chromogenic medium or McConkey agar) were re-inoculated onto 
tryptose blood agar plates (TBA) (NHLS Media Laboratory) and incubated under aerobic 
conditions at 37˚C overnight. Single isolates from the TBA plate were stored in Microbank beads 
(Pro Lab Diagnostics, Canada) at -80°C for further analysis. 
 
2.2.5   Identification and Antibiotic Susceptibility Testing 
All isolates were identified using API10S kits or API20E kits (BioMerieux, France), following 
the manufacturer’s instructions and based on >90% identity.  Standard Kirby Bauer disc 
diffusion testing (Bauer et al., 1966) was performed to determine susceptibility to penicillins, 
fluoroquinolones, aminoglycosides, cephalosporins, and carbapenems. Kirby-Bauer disc 
diffusion uses antibiotics impregnated into a filter-paper disc; these discs are placed onto an agar 
plate which has been inoculated with a standard inoculum of the organism in question. The 
antibiotics diffuse into the agar, resulting in inhibition of bacterial growth around the disc. The 
diameter of the zone is measured and interpreted using established interpretive criteria to classify 
isolates as susceptible, intermediate or resistant.  
 
Bacterial isolates were retrieved from Microbank beads and inoculated onto fresh TBA plates. A 
single colony was streaked onto TBA plates and incubated overnight at 37°C under aerobic 
condition to obtain pure cultures. Three to four colonies were inoculated in 3 ml of purified 
water in small glass tubes using sterile swabs and vortexed briefly. The turbidity of the 
suspension was determined using the DensiCHEK (Biomérieux, France) to obtain 0.45-0.5 
McFarland (equivalent to 1 - 2 x 10
8
 CFU/mL). Clearly labeled Mueller Hinton agar plates 
(NHLS Media Laboratory) were inoculated using fresh swabs, and the plate was rotated to 
ensure that the entire surface of the plate was covered. The selected antibiotics were placed onto 
the agar plate using an antibiotic disc dispenser (Mast Laboratories, UK). The plates were 
incubated aerobically for 16 - 18 hours at 37°C. Every procedure was carried out on a 
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decontaminated bench and around a Bunsen burner to reduce the risk of contamination. After 
incubation, the zone diameter of each antibiotic was measured and interpreted using the Clinical 
and Laboratory Standards Institute (CLSI) 2016 guidelines. Multi-drug resistant (MDR) isolates 
were defined as being resistant to one agent in at least three different classes of antibiotics 
(Basak et al., 2016) 
 
Suspected carbapenem non-susceptible isolates (based on disc diffusion results) were confirmed 
using gradient diffusion strips (Liofilchem s.r.l., Italy) for determination of ertapenem, 
imipenem, and meropenem MICs. The strips are impregnated with the antibiotic in a gradient. 
One end of the strip has a high concentration, decreasing over the length of the strip. The strips 
are placed on a previously inoculated agar plate and release the antibiotic into the agar. After 
incubation, the growth around the strip can be seen as a symmetrically inhibited ellipse. Mueller 
Hinton agar plates were inoculated as described above, and ertapenem, imipenem and 
meropenem strips were placed at the middle of the agar plates and incubated as previously 
described. The plates were read and interpreted using CLSI 2016 guidelines. 
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2.3 Results  
2.3.1 Isolate Numbers 
Stool samples were collected from a total of 50 participants of the TB-CHAMP study at baseline. 
Fifty-two E. coli isolates were obtained from 43 (86%) of the participants, and seventeen 
Klebsiella spp (K. oxytoca and K. pneumoniae) were isolated from 14 (28%) of the participants 
(Figures 2.1 & 2.2). Seven of the participants were colonized by neither E. coli nor Klebsiella 
spp. 
 
 
Figure 2.1: The proportion of children with E. coli isolates resistant to the cefpodoxime and 
ertapenem antibiotics. 
50 children 
43 had atleast one 
E. coli in stool 
0 had  E. coli from around 
the ertapenem disc 
13 had E. coli from around 
the cefpodxime disc 
0 had E. coli  from 
around both discs 
7 had no E. coli in 
stool 
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Figure 2.2: The proportion of children with Klebsiella isolates resistant to the cefpodoxime and 
ertapenem antibiotics 
 
All samples where isolates were visible in the zone of inhibition around cefpodoxime on the 
McConkey agar also had isolates which were identified as putative ESBL producers on the 
CHROMagar ESBL. The yield from both approaches was evaluated for the first 30 samples and 
since the performance of cefpodoxime on McConkey agar and CHROMagar ESBL was identical 
(100%), the former was adopted for the rest of the study.   
 
2.3.2  AST 
2.3.2.1   Disc Diffusion 
Of the 52 E. coli isolates, 33 (63%) were ampicillin-resistant, 4 (8%) β-lactamase inhibitor-
resistant, 21 (40%) quinolone-resistant, 3 (6%) aminoglycoside-resistant and 13 (25%) 
cephalosporin-resistant. All 17 of the Klebsiella isolates (100%) were ampicillin-resistant, 4 
(24%) β-lactamase inhibitor-resistant, 6 (35%) quinolone-resistant, 6 (35%) aminoglycoside-
resistant, 8 (47%) cephalosporin-resistant and 1 (6%) carbapenem-resistant. However, as these 
proportions are influenced by the sampling strategy, and by the fact that multiple isolates were 
50 children 
14 had at least one 
Klebsiella isolate in 
stool 
1 had a Klebsiella isolate from 
around the ertapenem disc 
8 had Klebsiella isolates from 
around the cefpodxime disc 
1 had Klebsiella isolates 
from around both discs 
36 had no Klebsiella 
isolate in stool 
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obtained from some participants, it is more useful to present the data as a percentage of the 
children who carried isolates that were non-susceptible to the various antimicrobials, as shown in 
Table 2.1. Based on the disc diffusion susceptibility testing, 21 (42%) of the participants were 
colonized by quinolone-resistant isolates and 18 (36%) were colonized by cephalosporin-
resistant isolates (possible ESBL-producers). All participants from whom cephalosporin-resistant 
isolates were obtained also carried cephalosporin-susceptible isolates. 
Overall, sixty-six percent (66%) of the participants were colonized by isolates resistant to at least 
one antibiotic, while 17 (34%) of the participants were colonized by MDR isolates. 
 
Table 2.1: Proportion of children colonized with organisms resistant to listed antibiotics 
Antibiotic E. coli (%) Klebsiella spp. (%) Both E. coli and 
Klebsiella spp. (%) 
Either E. coli or 
Klebsiella spp. (%) 
Amoxicillin 52 28 18 62 
Amoxicillin-
clavulanate 
8 8 2 12 
Nalidixic acid 36 12 6 42 
Ciprofloxacin 24 10 4 30 
Gentamicin 6 12 2 16 
Amikacin 0 2 0 2 
Cefuroxime 26 16 6 36 
Cefotaxime 26 16 6 36 
Ceftazidime 16 16 4 28 
Cefepime 26 16 6 36 
Ertapenem 0 2 0 2 
Imipenem 0 2 0 2 
 
2.3.2.2   Minimum Inhibitory Concentration 
One K. pneumoniae isolate (identified from around the ertapenem disc) had reduced zone sizes 
for imipenem and ertapenem. Carbapenem MICs, determined by gradient diffusion, were 2 
μg/ml, 1 μg/ml, and 0.5 μg/ml for ertapenem, imipenem, and meropenem respectively. Based on 
the 2016 and 2018 CLSI guidelines, the isolate was resistant to ertapenem but susceptible to 
imipenem and meropenem. 
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2.4 Discussion 
Antibiotic susceptibility testing is vital to assist with choosing appropriate antibiotics, and thus 
improve the likelihood of success of antibiotic therapy (Kerr, 2005). This chapter described the 
antibiotic resistance profile of isolates (E. coli and Klebsiella spp.) obtained from stool samples 
from healthy children in Cape Town. 
 
The cefpodoxime disc used on the McConkey agar for the selection of putative ESBLs was as 
effective as the CHROMagar ESBL and can be used as a test to select presumptive ESBL-
producing microorganisms (Gazin et al., 2012). A similar study was done by Huang et al.  using 
ceftazidime on McConkey agar compared to CHROMagar ESBL, and the specificity was >95% 
(Huang et al., 2010). The performance of the cefpodoxime against the CHROMagar ESBL is 
expected since cefpodoxime is currently the drug of choice incorporated in chromogenic media 
Gazin et al.  (2012). 
 
Unsurprisingly, E. coli was isolated from the stool of the majority of participants. E. coli has 
been reported as one of the most common enteric organisms (Amani et al., 2015; Kebede et al., 
2017). Most of the participants were colonized by amoxicillin resistant isolates which is also not 
surprising, given that amoxicillin is a commonly used agent. All Klebsiella isolates were 
amoxicillin-resistant because Klebsiella spp. contains a chromosomally-mediated blaSHV-1 
(Babini & Livermore, 2000; Chaves et al., 2001). 
 
Of concern is the finding that 42% and 36% of the participants were colonized by quinolone and 
cephalosporin-resistant isolates, respectively. Colonization by aminoglycoside resistant isolates 
was also seen in 16% of the participants. Colonization by quinolone-resistant isolates (E. coli) 
has been reported even in the Amazon forest where there is no selection pressure. In that setting, 
the rates of colonization in children were 45% for nalidixic acid and 15% for ciprofloxacin 
(Pallecchi et al., 2012). Quinolone resistance in E. coli isolates from healthy children in Peru and 
Bolivia increased between 2002 to 2005, from 35% to 57% for nalidixic acid and 18% to 33%  
for ciprofloxacin (Bartoloni et al., 2008). Similar to the above-mentioned findings we had 36% 
and 24% of the participants colonized by nalidixic acid and ciprofloxacin-resistant isolates 
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respectively. The resistance of E. coli and K. pneumoniae to ciprofloxacin in South African 
hospitals ranges from 8-20% and 21-51% respectively (Bamford et al., 2011; Brink et al., 2007). 
This is somewhat similar to what we have seen in our community isolates, although the data 
from SA hospitals does not differentiate between community-acquired and hospital-acquired 
isolates.  
 
A study conducted in a remote area in South America showed that quinolone resistance in E. coli 
was associated with the antimalarial drug chloroquine, which can select for mutations in 
topoisomerase resulting in quinolone resistance (Davidson et al., 2008). Quinolone resistance has 
also been associated with certain clones of E. coli, which could be a reason for its wide 
dissemination (Colpan et al., 2013; Johnson et al., 2010; Price et al., 2013). 
 
Previous findings of cephalosporin-resistant E. coli isolates colonizing pediatric and adult 
patients have been documented in Madagascar (22.1%) and Cameroon (54.06%) (Andriatahina 
et al., 2010; Cantón et al., 2008). However, the colonization rate of 36% from our study was 
higher than what has been reported in healthy children in the USA (4%) and Tunisia (6.6%) 
(Ferjani et al., 2017; Islam et al., 2015).  
 
In sub-Saharan Africa and Latin America, rates of resistance to third-generation cephalosporins 
in Enterobacteriaceae are as high as 46.5% and 87%  respectively (CDDEP, 2015; Leopold et al., 
2014). Cephalosporin resistance ranged from 39-87% in South African private hospitals (Brink 
et al., 2007) and 33% of clinical isolates from the public sector in South African hospitals were 
cephalosporin-resistant (Bamford C, Bonorchis K, Elliott E, 2009) which shows high resistance 
rates in isolates causing infections. While it is generally recognized that the prevalence of ESBLs 
is high in isolates from nosocomial settings in South Africa, at up to 58% (Bamford et al., 2009), 
the prevalence of ESBLs in community settings is thought to be lower. At least 34% of the 
children in our study carried an ESBL producing organism, which is higher than the 14% global 
rate of ESBL stool carriage in healthy children and adults reported from WHO-defined regions 
(Karanika et al., 2016). However, our carriage rate is similar to the overall rate (both hospitalized 
and healthy individuals) which was reported in Tanzanian children (34.3%). However, in 
Tanzania, the prevalence rate was 50.4% in pediatric patients and 11.6% in the community 
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(Tellevik et al., 2016). A previous study conducted in KwaZulu-Natal, South Africa, reported 
4.67% fecal ESBL carriage among healthy children in the community (Mahomed & Coovadia, 
2015). This is again lower than our findings in the Western Cape. However, our findings are 
similar to the prevalence of ESBL in E. coli and Klebsiella pneumoniae from hospitals across 
Africa which range from 21-33% (Andriatahina et al., 2010; Isendahl et al., 2012; Woerther et 
al., 2011).  The high rate of quinolone and cephalosporin resistance seen in our study supports 
the hypothesis that the community might be serving as a reservoir of antibiotic resistance which 
may have originated in nosocomial settings and become established in the community.  
 
The environment has also been reported to be a major reservoir in the dissemination of antibiotic 
resistance (Marti et al., 2013), and whether these environmental isolates may play a role in 
humans becoming colonized is yet to be established. The first study of the environmental 
resistome was published in 2006 (D’Costa, 2006). Morphologically different spore-forming 
bacteria were collected from the soil in various locations (agricultural, forest and urban) and 480 
strains of bacteria were screened for resistance against commonly used antibiotics including 
natural and synthetic derivatives. Multi-drug resistance was observed in all strains of spore-
forming bacteria. This study demonstrated that antibiotic resistance is widely disseminated in 
environmental bacteria (D’Costa et al., 2006). Grahan et al (2010) extracted DNA from 
agricultural soils in the Netherlands from 1940-2008 and found that antibiotic resistance existed 
even in the pre-antibiotic era. The blaCTX-M gene was also identified in soil prior to its 
emergence in clinical settings (Knapp et al., 2010).Tap water from Michigan, Ohio, contained 
bacteria resistant to amoxicillin, ciprofloxacin, gentamicin, rifampicin, and sulfisoxazole (Xi et 
al., 2009). In another study, blaTEM positive isolates in sewage were enriched after treatment 
(Lachmayr et al., 2009). The qnrA gene (associated with quinolone resistance) has been 
associated with the aquatic bacterium Shewanella algae (Chapter 1, subsection 1.5.1.1) (Poirel et 
al., 2005).  
 
A notable finding in our study was the presence of a single K. pneumoniae isolate resistant to 
carbapenems; this isolate was classified as extensively drug-resistant because it was resistant to  
all classes of antibiotics tested (Magiorakos et al., 2012). Carbapenem-resistant isolates with 
similar characteristics have been reported in South Africa (Brink et al., 2008, 2012) but not from 
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healthy children. At present, all carbapenemase positive Enterobacteriaceae isolates have been 
referral isolates from both public and private hospitals (Perovic et al., 2016). To the best of our 
knowledge, no carbapenem-resistant isolates have been reported from the community yet. While 
the participant from whom this isolate was cultured is a child based in the community, we do not 
have access to information related to his/her healthcare history, due to the blinded nature of the 
TB-CHAMP study. If there had been a history of recent hospitalization, for example, this may 
better explain the concerning presence of this resistant isolate. Though the isolate was resistant to 
ertapenem and imipenem in the disc diffusion susceptibility testing it was resistant to only 
ertapenem in the gradient diffusion assay. This might be because the zone diameter of imipenem 
was 19cm which is exactly the susceptibility breakpoint based on 2016 CLSI guidelines. 
 
Our findings demonstrate a relatively high prevalence (34%) of MDR Enterobacteriaceae in 
Cape Town. While the sample size is still small and analysis of additional children is ongoing, 
these resistance rates do highlight the need to better understand the epidemiology of 
antimicrobial resistance in the community, and to develop interventions (such as antimicrobial 
stewardship programs) that are focused on the community. Regular surveillance needs to be 
performed which will provide information to help regulate the use of antibiotics in the 
community. There may also be a need to implement infection control measures to prevent 
resistant bacteria from flowing from the community into the hospital. 
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Chapter 3 : Molecular Resistance Mechanisms and Strain Typing of Isolates 
collected from Stool Samples 
3.1 Introduction 
While phenotypic antibiotic susceptibility testing is vital for treatment, it fails to give 
information on the mechanisms of resistance. This information can help identify mechanisms 
which are likely to spread to other bacterial species via horizontal gene transfer (Anjum, 2015), 
and assists with understanding the epidemiology of antimicrobial resistance. Both singleplex and 
multiplex PCR assays were employed in this chapter to identify acquired resistance genes and to 
detect mutations responsible for resistance, focusing on resistance to beta-lactams and 
fluoroquinolones. 
 
Strain typing is a molecular technique which is a necessity in an epidemiological study. The use 
of strain typing allows us to describe the predominant strains circulating in the community, as 
well as to describe associations between strain type and presence of resistance. The most 
common molecular typing techniques used over the years include Restriction Fragment Length 
Polymorphism (RFLP), Pulsed-Field Gel Electrophoresis (PFGE), Random Amplified 
Polymorphic DNA (RAPD), Automatic Ribotyping, Repetitive Extragenic Palindromic (rep)-
PCR and Multi-Locus Sequence Typing (MLST) (Krawczyk et al., 2016; Ross et al., 2005; 
Tabit, 2016) 
 
This study makes use of rep-PCR because it is less time consuming, highly reproducible and 
discriminatory (Castro-Escarpulli et al., 2015). However, it requires specialized skills to analyze 
the results (Ross et al., 2005). rep-PCR is a DNA fingerprinting technique used to examine 
strain-specific patterns obtained from PCR amplification of repetitive DNA elements in a 
bacterial genome. Two major sets of repetitive elements are used for the typing, the repetitive 
extragenic palindromic (rep) elements which are 38-bp sequences consisting of six degenerate 
positions and a 5-bp variable loop between each side of a conserved palindromic stem. The 
palindromic nature of the rep elements and their tendency to form stem-loop structures have led 
to numerous functions for these highly conserved, dispersed elements (Krawczyk et al., 2016). 
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This chapter aimed to describe the antibiotic resistance mechanisms and strain diversity of the E. 
coli and Klebsiella spp. isolated from stool from healthy children, as described in Chapter 2. 
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3.2  Materials and Methods 
3.2.1   DNA Extraction 
A crude DNA extraction method was used to extract DNA from all isolates (n=49) collected as 
described in chapter 2. Isolates stored in microbank beads (Pro-Lab Diagnostics, Canada) were 
inoculated on TBA plates (NHLS Media Laboratory, Greenpoint, South Africa) and incubated at 
37˚C for 18 hours under aerobic conditions. After incubation, single colonies were resuspended 
in 400 µl nuclease-free water. The tubes were vortexed to homogenize the solution, and then 
incubated in a heating block at 95˚C for 30 mins, followed by freezing at -20˚C for 30 mins. Cell 
debris was sedimented by centrifugation (Sigma 1-15) for 10 mins at 14000 x g (Sigma Aldrich, 
Germany) and the supernatant containing the DNA was collected. Nuclease-free water was used 
as a negative control and was included in each extraction step. The extracted DNA was stored at 
-20°C. 
 
3.2.2   Detection of Resistance Genes 
3.2.2.1 PCR 
PCR was performed on all isolates which were resistant to carbapenems (n=1), cephalosporins 
(n=21) and quinolones (n=27) to screen for carbapenemase genes, ESBL genes, and quinolone-
resistance genes respectively. The multiplex PCRs were performed in a reaction mixture 
containing 12.5 µl of KAPA2G Multiplex Master mix (KAPA Biosystems, South Africa), 2 µl of 
template DNA, the relevant primer pairs and water to make up a final volume of 25µl. KAPA 
ReadyMix (KAPA Biosystems) was used for the singleplex PCRs, except for SHV for which 
KAPA2G Multiplex Master mix was used. The primer sequences and concentrations used in 
each reaction are described in Table 3.1. rpoB was used as an internal control in all the multiplex 
PCR reactions except for the assays targeting the qnr genes, as the rpoB primers interfered with 
the amplification of the qnrB gene. 
 
 
Stellenbosch University https://scholar.sun.ac.za
44 
 
 3.2.2.2  Gel Electrophoresis 
All amplicons were separated on 2% Seakem LE agarose (Lonza, South Africa) gel in 1X Tris-
acetate-ethylenediaminetetraacetic acid (TAE) buffer at 120 volts for 50 mins except for qnr 
genes which were separated for 90 mins. The band sizes were determined using New Biolabs 
100bp Ladder (New England Biolabs Inc.). The amplicons were visualized under UV light using 
the UVitec Cambridge Alliance 2 gel documentation system. 
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Table 3.1: Primer Sequences for PCR 
Target primers Concentration of 
primer  
Sequences (5’ – 3’) Size 
(bp) 
References  
qnrA qnrA-F 0.2 µM TCAGCAAGAGGATTTCTCA 627 Liu et al., 
2012 qnrA-R GGCAGCACTATTACTCCCA 
qnrB qnrB-F 0.2 µM GATCGTGAAAGCCAGAAAGG 469 Liu et al., 
2012 qnrB-R ACGATGCCTGGTAGTTGTCC 
qnrS qnrS-F 0.2 µM ACGACATTCGTCAACTGCAA 417 Liu et al., 
2012 qnrS-R TAAATTGGCACCCTGTAGGC 
gyrA gyrA-F 0.2 µM ACGTACTAGGCAATGACTGG 191 Liu et al., 
2012 gyrA-R AGAAGTCGCCGTCGATAGAA 
parC ParC-F 0.2 µM TGTATGCGATGTCTGAACTG 264 Liu et al., 
2012 ParC-R CTCAATAGCAGCTCGGAATA 
blaCTX-M CTX-F 0.2 µM ATGTGCAGYACCAGTAARGTKATGGC 593 Monstein et 
al., 2007 CTX-R TGGGTRAARTARGTSACCAGAAYCAGCGG 
blaSHV SHV-F 0.24 µM ATGCGTTATATTCGCCTGTG 747 Monstein et 
al., 2007 SHV-R TGCTTTGTTATTCGGGCCAA 
blaTEM TEM-F 0.2 µM TCGCCGCATACACTATTCTCAGAATGA 445 Monstein et 
al., 2007 TEM-R ACGCTCACCGGCTCCAGATTTAT 
blaVIM VIM-F 0.2 µM GATGGTGTTTGGTCGCATA 390 Zowawi et 
al., 2014 VIM-R CGAATGCGCAGCACCAG 
blaIMP IMP-F 0.2 µM CTACCGCAGCAGAGTCTTTGC 591 Zowawi et 
al., 2014 IMP-R GAACAACCAGTTTTGCCTTACC 
blaKPC KPC-F 0.2 µM ATCTGACAACAGGCATGACG 452 Zowawi et 
al., 2014 KPC-R GACGGCCAACACAATAGGTG 
blaOXA OXA-F 0.2 µM GCGTGGTTAAGGATGAACAC 438 Zowawi et 
al., 2014 OXA-R CATCAAGTTCAACCCAACCG 
blaNDM NDM-F 0.2 µM GCAGGTTGATCTCCTGCTTG 203 Zowawi et 
al., 2014 NDM-R ACGGTTTGGCGATCTGGT 
blaGES GES-F 0.2 µM GTTTTGCAATGTGCTCAACG 371 Weldhagen 
and Prinsloo, 
2004 
GES-R TGCCATAGCAATAGGCGTAG 
rpoB 
  
rpoB-F ESBL PCR assays: 
0.2 µM.  
Carbapenemase 
PCR assays: 0.08 
µM 
AACCAGTTCCGCGTTGGCCTGG 1088 
  
(Hoffmann 
& 
Roggenkamp 
2003) 
  
rpoB-R CCTGAACAACACGCTCGGA 
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3.2.2.3  Control Strains 
blaTEM, blaSHV and blaCTX-M, qnrB and qnrS positive controls were obtained from a 
previous study in the department (Table 3.2), where isolates with qnrB and qnrS had been 
identified by analysis of whole genome sequences. The amplification products of these controls 
had been previously confirmed by Sanger sequencing. Unfortunately, a qnrA positive control 
was not included in this assay, as we were unable to source any positive controls from South 
African collaborators, or overseas collaborators in Freiburg, Wurzburg, Cardiff or Nairobi.  E. 
coli ATCC25922 and K. pneumoniae ATCC700603 were used as positive controls for parC and 
gyrA singleplex PCR. (Table 3.2).  
 
Table 3.2: Positive controls used for PCR 
POSTIVE CONTROLS SOURCE 
Carbapenemase controls 
National Institute for 
Communicable Diseases 
(NICD, South Africa) 
satellite unit at Groote 
Schuur Hospital  
blaIMP K. pneumoniae  
blaOXA K. pneumoniae  
blaVIM K. pneumoniae  
blaGES K. pneumoniae  
blaNDM K. pneumoniae  
blaKPC K. pneumoniae  
ESBL controls 
A previous study in the 
Department of Medical 
Microbiology, 
Stellenbosch University. 
blaSHV Single E. coli isolate 
positive for all three 
genes 
blaTEM 
blaCTX-M 
qnr controls 
qnrA NA 
qnrB Single E. coli isolate 
positive for both 
genes 
qnrS 
Detection of mutations National Health 
Laboratory Service 
(NHLS) diagnostic 
laboratory at Tygerberg 
Hospital (TBH) 
gyrA 
E. coli ATCC25922 
K. pneumoniae 
ATCC700603 
parC 
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3.2.2.4   Carbapenemase Genes 
Isolates with reduced susceptibility to carbapenems were subjected to a touchdown multiplex 
PCR assay to differentiate 6 carbapenemase genes – blaVIM, blaIMP, blaGES, blaKPC, 
blaOXA and blaNDM (Weldhagen & Prinsloo, 2004; Zowawi et al., 2014). The multiplex PCR 
was split in two reactions: blaVIM, blaIMP, blaOXA and blaGES, blaKPC, blaNDM (Table 
3.3), because the band sizes of blaKPC and blaOXA differ by only 14 bp which would be 
difficult to differentiate on a gel image from a single assay.  
 
Table 3.3: Cycling conditions for the carbapenemase touch down multiplex PCR 
 
Temperature(˚C) Time No. of cycles 
Initial denaturing 95 3min 1 
Denaturing 95 15sec 
20 Annealing 68 30sec 
Extension 72 1min 
Denaturing 95 15sec 
10 Annealing 62 30sec 
Extension 72 1min 
Final Extension 72 5min 1 
Hold 4 ∞  
 
3.2.2.5   Extended-spectrum β-lactamase genes 
Extended-spectrum beta-lactamase genes from phenotypically cephalosporin resistant E. coli and 
Klebsiella isolates were characterized using a multiplex PCR assay that targets the blaCTX-M, 
blaSHV and blaTEM families (Monstein et al., 2007) (Table 3.4). 
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Table 3.4: Cycling conditions for the ESBL multiplex PCR 
 
 
 
 
 
 
 
 
 
 
Molecular Classification of blaTEM and blaSHV Genes by DNA Sequence Analysis 
All variants of blaCTX-M have the extended spectrum activity characteristic of ESBLs, but 
many blaSHV and blaTEM variants do not have this extended-spectrum activity. All blaTEM 
and blaSHV positive isolates were subjected to a singleplex PCR (for either blaTEM, or 
blaSHV, or both, as appropriate), followed by Sanger sequencing to differentiate between genes 
encoding enzymes with and without extended spectrum activity. Fifteen to twenty microlitres of 
the amplicons were sent for Sanger sequencing at Inqaba BioTech (South Africa), using the 
forward PCR primers. The sequencing was performed using BrilliantDye
TM
 Terminator V3.1. 
 
The nucleotide sequences were edited and analyzed using BioEdit Sequence Alignment Editor 
version 7.2.5. blaSHV sequences were converted to amino acid sequences and compared to 
blaSHV protein sequences because the DNA sequences have multiple synonymous nucleotide 
substitutions, which made the nucleotide sequences difficult to interpret. 
 
3.2.2.6   Quinolone Resistance Mechanisms 
qnr genes 
Quinolone-resistant isolates (resistant to nalidixic acid or ciprofloxacin) were analyzed for the 
presence of qnr genes (qnrA, qnrB, and qnrS) using a multiplex PCR (Liu, Liao, et al., 2012), 
using the cycling conditions described in table 3.5. 
  Temperature(˚C) Time No. of cycles 
Initial denaturing           
95 
3min 1 
Denaturing                 15sec 
35 
 
Annealing   
 
67 30sec 
 
Extension 
72 
30sec 
Final Extension 3min 1 
Hold 4 ∞ 
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Table 3.5: Cycling conditions for the qnr multiplex PCR and singleplex parC and gyrA PCRs 
 
 
 
 
 
 
 
 
 
parC and gyrA Mutations 
Singleplex PCR was used to amplify the gyrA and parC genes from all quinolone-resistant 
isolates  (Liu, Liao, et al., 2012), as shown in Table 3.5. The PCR products were sequenced at 
Inqaba BioTech. The initial set of PCR products were sequenced using both PCR primers, but 
since the forward sequence covered the positions of all the expected mutations, the remaining 
products were sequenced using only the forward primer. BioEdit software was used to align and 
detect mutations on the gyrA and parC loci. The gyrA and parC sequences were compared with 
respective wild-type sequences from NCBI with accession number NC_000913. 
 
3.2.3 Repetitive Palindromic Sequence (rep)-PCR 
All isolates were subjected to rep-PCR (Versalovic et al., 1991) to generate a specific DNA 
pattern or fingerprint to determine the genetic relatedness of the isolates; including available 
matched susceptible and resistant isolates. Based on Higgins et al, (2012) classification method, 
similarity of 95% or above would indicate relatedness, while unrelated strains had similarity of 
<95%.  
 
 The primers used for the rep-PCR include; REP-1-F 5′- ICGICTTATCIGGCCTAC-3′ and REP-
2-R: 5′-CGGICTACIGCIGCIIII-3′ as previously described by Versalovic et al., (1991).  The 
PCR was performed in a reaction mixture containing 12.5 µl of KAPA2G Multiplex Master mix, 
  Temperature(˚C) Time No. of cycles 
Initial denaturing           
95 
3min 1 
Denaturing                 15sec 
35 
 
Annealing   
64 (qnr) 
60 (gyrA; parC) 30sec 
 
Extension  
72 
 
30sec 
Final Extension 3min 1 
Hold 4 ∞   
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2 µl of template DNA, the primer pairs (REP-1-F & REP-2-R) and water to make up a final 
volume of 25 µl. The concentration of each primer used was 0.2 µM; and the cycling conditions 
are described in Table 3.6. 
 
 
Table 3.6: Cycling conditions for rep-PCR 
 
Temperature(˚C) Time No. of cycles 
Initial denaturing                     95 5min 1 
Denaturing                              95 30sec 
30 Annealing           40 30sec 
Extension                                72 8min 
Final Extension                       72 16min 1 
hold                                           4 ∞   
 
Amplicons were separated on 2% Seakem LE agarose gel in 1X TAE buffer at 80 volts for 84 
mins. The band sizes were determined using DirectLoad
™
 Wide Range DNA Marker (Sigma, 
Aldrich, Germany). The amplicons were visualized as previously described. The rep-PCR gel 
image was incorporated into GelComparII Bionumerics (version 7.5) and a phylogenetic tree 
was generated using the dice-band approach with the UPGMA algorithm. Isolates with 95% and 
above similarity were considered related. 
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3.3 Results 
3.3.1 Identification of Carbapenemase Genes 
Multiplex PCR showed that the single carbapenem-resistant K. pneumoniae isolate (K4) 
harbored the blaNDM carbapenemase gene (Figure 3.1) 
 
 
Figure 3.1. Carbapenemase Multiplex PCR. 2% agarose gel showing common carbapenemase 
genes blaIMP, blaVIM, blaOXA (left side of gel) and blaNDM, blaKPC and blaGES (right side 
of gel), with an internal control (rpoB gene). M = Kapa Universal DNA Marker, PTC= Positive 
Template Control and NTC= No Template Control. K4 = Klebsiella isolate. 
 
3.3.2 Identification and Characterization of ESBL Genes 
Thirteen E. coli and 8 Klebsiella spp. isolates were resistant to cephalosporins and therefore 
predicted to be ESBL producers. Multiplex PCR was used to identify the three most common 
ESBL gene families; blaSHV, blaCTX-M, and blaTEM. An example of one of the agarose gels 
showing the presence of different ESBL-related genes in a selection of isolates is shown in 
Figure 3.2 with the internal control, rpoB, present in all isolates. All thirteen (100%) of the 
cephalosporin resistant E. coli isolates harbored a blaCTX-M gene and 7 (54%) had an 
additional blaTEM gene. However, none of the E. coli isolates harbored the blaSHV gene. 
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blaSHV was detected in all 8 (100%) of the cephalosporin resistant Klebsiella isolates of which 
7 (88%) also harbored blaCTX-M and blaTEM genes (Figure 3.3). 
 
 
Figure 3.2: ESBL Multiplex PCR. 2% agarose gel showing ESBL family genes (blaCTX-M, 
blaTEM, and blaSHV) with an internal control (rpoB) gene. M = KAPA Universal DNA Ladder. 
PTC = Positive Template Control. K = Klebsiella isolates and E = E. coli isolates. 
 
 
Figure 3.3: Distribution of blaCTXM, blaTEM and blaSHV genes in cephalosporin-resistant E. coli 
isolates (A) and Klebsiella spp.(B). 
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All blaTEM genes were identified as blaTEM-1 based on 99.2% DNA sequence identity to a 
published blaTEM-1 sequence (NC_022885.) over 45-47% of the blaTEM-1 gene. Therefore, all 
blaTEM genes were identified as β-lactamases without extended spectrum activity. 
Three of the blaSHV genes were identified as blaSHV-1, four were identified as blaSHV-11 and 
one was identified as blaSHV-26 based on 100% amino acid identity to published blaSHV-1 
(DQ478720.), blaSHV-11 (NC 019157.), and blaSHV-26 (AF227204.) respectively, with 79.7% 
coverage. Therefore, all the blaSHV genes were identified as β-lactamases without extended 
spectrum activity. The one Klebsiella isolate with only blaSHV and no blaCTX-M or blaTEM 
(Fig 3.3) was the isolate with the blaNDM carbapenemase. 
Eighteen (36%) of the children were colonized by one or more ESBL-producing isolates, all of 
which were blaCTX-M related. 
 
3.3.3 Quinolone Resistance Genes 
Plasmid-mediated quinolone resistance genes 
Of the 21 quinolone-resistant E. coli isolates, 5 (24%) harbored qnrS while of the 6 quinolone-
resistant Klebsiella isolates, 4 (67%) had qnrB.  Overall, 8 (16%) of the participants were 
colonized by isolates with plasmid-mediated quinolone resistance genes (Table 3.7). Two (4%) 
of the participants were colonized by E. coli isolates with both PMQR genes and ESBL genes 
while 4 (8%) were colonized by Klebsiella isolates with both PMQR genes and ESBL genes. 
 
Chromosomal Mutations 
All of the quinolone-resistant isolates had at least a single mutation in either the parC or gyrA 
genes. The most common mutation in E. coli was S83L in gyrA and it was often (62%) coupled 
with a D87N mutation in gyrA (Table 3.7). Seven E. coli isolates had only a single mutation in 
gyrA (S83L in six; D87W in one); all seven of these isolates were resistant to nalidixic acid but 
ciprofloxacin susceptible. All isolates with at least two mutations (or a single mutation plus a 
qnr-gene) were resistant to both nalidixic acid and ciprofloxacin.  
 
All quinolone resistant Klebsiella isolates, except K4, had only double parC mutations, S129A 
and A141V, and no mutation in gyrA (Table 3.8). Isolate K4 (the only carbapenem-resistant 
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isolate) had three mutations (S80I, S129A, and A141V) in parC and a double mutation in gyrA 
(D87A and S83L). All Klebsiella isolates were resistant to both nalidixic acid and ciprofloxacin. 
All isolates with plasmid-mediated quinolone resistance also had mutations in either parC or 
gyrA. 
 
Table 3.7: Mechanisms of resistance in quinolone-resistant E. coli isolates 
E. coli isolate Quinolone susceptibility Quinolone resistance gene and codon 
  
Nalidixic 
Acid 
Ciprofloxacin PMQR gyrA parC 
 gene/codon     qnrB qnrS 83 87 80 84 
E. 1 R S     S83L WT WT WT 
E. 2 R R     S83L D87N S80I WT 
E. 3 R S     S83L WT WT WT 
E. 4 R R     S83L D87N S80I E84V 
E. 5 R R   X S83L D87N S80R WT 
E. 6 R R     S83L D87N S80I WT 
E. 7 R R   X S83L D87N S80R WT 
E. 8 R S     S83L WT WT WT 
E. 9 R R     S83L D87N S80I E84V 
E. 10 R S     WT D87W WT WT 
E. 11 R R   X S83L D87N S80I WT 
E. 12 R R     S83L D87N S80I WT 
E. 13 R R   X S83L D87N S80I WT 
E. 14 R R     S83L D87N S80I WT 
E.17 R R     S83L D87N S80I WT 
E. 19 R S     S83L WT WT WT 
E. 20 R R   X S83L WT WT WT 
E. 21 R R     S83L D87N S80I WT 
E. 22 R S     S83L WT WT WT 
E. 23 R R     S83L D87N S80I WT 
E. 24 R S     S83L WT WT WT 
 
 
 
 
 
Stellenbosch University https://scholar.sun.ac.za
55 
 
Table 3.8: Mechanisms of resistance in quinolone-resistant Klebsiella isolates 
Klebsiella isolates 
Isolate ID Nalidixic 
Acid 
Ciprofloxacin PMQR parC gyrA 
 gene/codon   qnrB qnrS 80 129 141 83 87 
K. 1 R R     WT S129A A141V WT WT 
K.2 R R     WT S129A A141V WT WT 
K. 3 R R X   WT S129A A141V WT WT 
K. 4 R R X   S80I S129A A141V S83L D87A 
K. 5 R R X   WT S129A A141V WT WT 
K. 7 R R X   WT S129A A141V WT WT 
 
3.3.4 Strain Typing 
rep-PCR was performed to determine the relatedness of the isolates. Since the culture and 
selection aimed to collect multiple isolates from the same individual, the typing included isolates 
from the same stool sample. There were 13 pairs of E. coli isolates and 8 pairs of Klebsiella 
isolates from the same sample. Each of the isolates within a pair was also unrelated, with the 
similarity between the isolates and individual pairs ranging from 20.6 to 92.6% (Figure 3.4 & 
3.3). 
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Figure 3.2: Genetic relatedness of E. coli isolates  
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Figure 3.3: Genetic relatedness of Klebsiella isolates 
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3.5  Discussion  
While mutations in chromosomal genes (such as gyrA and parC) are a well-described cause of 
resistance (Woodford & Ellington, 2007), plasmid-mediated resistance genes are of greater 
concern because these mobile genetic elements are likely to be transferred between bacterial 
species. Plasmid-mediated antibiotic resistance genes are widely disseminated and a global threat 
(Burmeister, 2015). Plasmids harbor genes which have many functions, including virulence 
factors and antibiotic resistance, that help the bacteria to survive in their environment and to 
withstand the antibiotics that are used to treat them (Ramirez et al., 2015).  
 
One carbapenem-resistant Klebsiella isolate (K4) harbored the blaNDM carbapenemase gene. 
Though this isolate was resistant to cephalosporins, it had only blaSHV-1 (non-ESBL), 
suggesting that the blaNDM gene conferred cephalosporin resistance. The first blaNDM positive 
isolate described in South Africa was resistant to all antibiotics except colistin and tigecycline 
which is a peculiar susceptibility profile for the blaNDM gene (Lowman et al., 2011) but is 
similar to our findings. blaNDM-positive isolates with similar susceptibility profiles have been 
reported in Pakistan, India and the UK (Kumarasamy et al., 2010). 
 
 
The most common ESBL gene was blaCTX-M in both E. coli and Klebsiella isolates with an 
overall rate of 94% among the predicted ESBL-producing isolates. Only one (K4) of the ESBL-
producing Klebsiella isolates did not harbor blaCTX-M. Interestingly, this isolate contained a 
blaSHV-1 gene which is not an ESBL. The isolate was phenotypically resistant to 
cephalosporins, which might be attributed to the presence of blaNDM as described previously. 
All the other blaSHV (blaSHV-1, blaSHV-11, and blaSHV-26) and blaTEM (blaTEM-1) genes 
detected by PCR in our isolates lack extended spectrum activity and are not regarded as ESBLs  
(Barguigua, El Otmani, et al., 2013). 
 
The predominance of blaCTX-M related ESBLs is consistent with global findings. A previous 
study in Cambodia and Cameroon reported 100% of ESBL-producing E.coli from clinical 
isolates harbored blaCTX-M (Lonchel et al., 2012; Ruppé et al., 2009). In healthy children from 
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Tunisia, 6 out of 7 ESBL-producing  E. coli harbored blaCTX-M (Ferjani et al., 2017). The 
prevalence of blaCTX-M in ESBL-producing clinical Enterobacteriaceae isolates was 90% and 
94.7% in Canada and Tanzania respectively (Chaubey et al., 2010; Tellevik et al., 2016). In 
South Africa, 95% of ESBL-producing E. coli recovered from urine and pus swabs from 
community hospitals harbored blaCTX-M in both children and adults (Peirano & Pitout, 2010). 
 
Two out of 5 qnrS-positive E. coli isolates harbored blaCTX-M whilst 3 out of 4 qnrB-positive 
Klebsiella isolates had blaCTX-M. qnr genes are known to co-exist with ESBLs because they 
are often located on the same plasmids (Crémet et al., 2011). Interestingly the only PMQR gene 
detected in our E. coli isolates was qnrS, while in Klebsiella isolates, we only detected qnrB.  In 
Iran, a predominance of qnrS and qnrB has been reported in E. coli and Klebsiella isolates 
respectively (Mirzaii et al., 2018). qnr genes, by themselves, do not confer quinolone resistance, 
but promote the selection of higher-levels of resistance, increasing the effect of parC and gyrA 
mutations on quinolone MICs (discussed in chapter 1, section 1.5.1). 
 
Mutations in the parC and gyrA genes are well known to cause resistance to quinolones. All 
quinolone-resistant isolates had at least one mutation in either the parC or gyrA genes. E. coli 
isolates with mutations in both gyrA and parC were resistant to nalidixic acid and ciprofloxacin 
while those with mutations in only gyrA were resistant to only nalidixic acid. A similar finding 
has been reported by Liu et al, (2012) and Nouri et al, (2016). In previous studies, eighty-three 
of 92 isolates with at least three point mutations showed ciprofloxacin MICs of 32 μg/ml while 
all isolates with a single point mutation in gyrA, were not resistant to ciprofloxacin (MICs ranged 
from 0.25 to 2 μg/ml) (Onseedaeng & Ratthawongjirakul, 2016). However, one E. coli isolate 
from our study had a single mutation in gyrA as well as the qnrS gene and was resistant to 
nalidixic acid and ciprofloxacin, which supports the hypothesis that PMQR genes promote the 
selection of higher-level resistance (Guan et al., 2013). E. coli isolates with double mutations in 
gyrA had at least one mutation in parC, while there were no isolates with a single mutation in 
gyrA and a mutation in parC. This may support the hypothesis that gyrA appears as a primary 
fluoroquinolone target in Enterobacteriaceae (Piekarska et al., 2015).  
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Sixty-two percent of the quinolone-resistant E. coli isolates had the double S83L and D87N 
mutations in gyrA. A similar mutation pattern was reported in healthy children from the Amazon 
forest (Pallecchi et al., 2012).  The S80I mutation in parC, seen among 43% of our isolates, has 
also been reported by Onseedaeg et al, (2016) in clinical isolates. 
 
Amongst the Klebsiella isolates, only one isolate had a mutation in gyrA (the single carbapenem-
resistant isolate), while in the parC genes the most common mutations were S129A and A141V, 
similar to what has been reported by Nouri et al, (2016) and Kao et al, (2016) in Pseudomonas 
aeruginosa and E. coli respectively. The Klebsiella isolates with mutations in only the parC gene 
were resistant to ciprofloxacin. This is in line with what Liu et al reported in 2012, namely that 
mutations in parC alone lead to higher ciprofloxacin MICs in E. coli isolates. However, the 
mutations occurred at position S80I and the MICs ranged from 0.125 to 128 mg.l
-1 
 (Liu, Liao, et 
al., 2012). Almost all the Klebsiella isolates with mutations in only parC and that were resistant 
to ciprofloxacin harbored PMQR genes; this may also support the hypothesis mentioned earlier. 
However, one isolate (K1) had double mutations in parC (S129A and A141V) and no PMQR 
gene detected but was resistant to ciprofloxacin. 
Results from the rep-PCR show that the E. coli and Klebsiella isolates from the stool of the 
participants were unrelated, ESBL-producing and quinolone-resistant isolates were not 
associated with a particular lineage. This is not surprising given the great microbial diversity to 
be expected in stool samples and given that the participants are not epidemiologically related. 
Interestingly, even isolates from within the same patient sample were unrelated, highlighting the 
existence of diversity within a patient sample. This finding confirmed what has been published 
by Schlager et al., (2002), showing that the normal intestinal flora is diverse and the composition 
changes over time. Similar findings have also been published by Caugant et al., (1981). Factors 
such as diet and lifestyle have been reported to influence variations in stool microbiota 
(Lozupone et al., 2012; Senghor et al., 2018) 
 
Our findings report a high prevalence of plasmid-mediated quinolone and cephalosporin 
resistance genes in E. coli and Klebsiella isolates in children in Cape Town. A single 
carbapenem-resistant isolate harboring blaNDM was also detected, which is concerning. 
Coexistence of two or more resistance genes has also been recorded in our study. This increases 
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the risk of the children being infected by resistant isolates since plasmid-mediated resistance can 
disseminate among bacteria. Appropriate measures such as hand-washing and personal hygiene 
need to be encouraged in schools and homes to reduce the risk of infections, and the need to use 
antibiotics judiciously must be emphasized. 
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Chapter 4 :  Exposure of Stool Samples to Sub-clinical Concentrations of 
Selected Antibiotics 
4.1 Introduction 
The indiscriminate and inappropriate use of antibiotics in humans, animals and the environment 
(Andersson & Hughes, 2014) results in regular exposure of bacteria (including those found as 
normal human flora) to varying (and sometimes sub-lethal) concentrations of antibacterial agents 
(Baquero & Negri, 1997). These low-level concentrations may stimulate the emergence of low-
level resistance which can serve as a pacesetter for high-level resistance (Baquero, 2001). 
 
Studies that have examined the effect of in-vitro exposure of organisms to antibiotics have 
improved our understanding of resistant microorganisms (Gullberg et al. 2011; Sandegren 2014; 
Andersson & Hughes 2014). Studies investigating in-vitro exposure have shown a link with the 
emergence of resistance in both microbial populations and sub-populations (Cantón & Morosini, 
2011; Gullberg et al., 2011; Sandegren, 2014). Understanding the association between antibiotic 
exposure and development of resistance is important to better understand the implications of 
antimicrobial use, and potentially to design treatment regimens that may reduce the emergence of 
resistance (Baquero, 2001). 
 
Sub-MIC levels of β-lactams and fluoroquinolones have been documented to select for and 
enrich resistance (Couce & Blázquez, 2009) (chapter 1, section 1.6). Quinolones have been 
reported to have the highest recovery rate in stool samples (De Lastours et al., 2014). Since the 
TB-CHAMP study is evaluating the efficacy of levofloxacin for MDR-TB prophylaxis (Tb-
Champ protocol, 2015)(Tb-Champ protocol, 2015) it creates an opportunity to do an in-vitro 
pilot study to examine the effect of the intervention on the carriage of resistant organisms in the 
participants. 
 
Most in vitro antibiotic exposure studies differ in the duration of exposure, classes of antibiotics 
used and most if not all use bacterial isolates and not complex human samples (Cantón & 
Morosini, 2011; Olofsson & Cars, 2007). This chapter aims to investigate the effects of antibiotic 
exposure on the transfer and acquisition of resistance in stool using an in vitro model. As a novel 
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approach was used in this study, the practically of the model was evaluated and used to advise 
future studies. 
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4.2 Materials and Methods 
4.2.1 Antibiotic Exposure 
This phase of the study aimed to mimic the exposure of organisms in stool samples to sub-
clinical concentrations of antibiotics (as may occur when antibiotics are administered 
systemically) and to describe how this influences the carriage and development of resistance in 
organisms in the stool sample. The antibiotics chosen were amoxicillin and ciprofloxacin (as two 
commonly used oral agents), and colistin. While colistin is not commonly used and is only 
administered intravenously to humans, it is sometimes added to animal feed. Given its 
importance as a (human) antibiotic of last resort, and with emerging reports of colistin resistance, 
we included it in this pilot study to potentially inform future studies that would more 
appropriately focus on its effects in animals. 
  
For the purposes of this pilot, the first 10 stool samples received were used. One hundred 
micrograms (100 µg) of each of these 10 baseline stool samples was resuspended in 10 ml of 
saline to make up a final concentration of 10 mg/ml. One thousand microliters (1000 µl) of the 
stool suspension was aliquoted into four 20 ml sterile vials, each vial containing 1000 µl of one 
of the three selected antibiotics, as well as one vial with no antibiotic. After adding the stool 
sample, the final concentration of each antibiotic in the stool suspension was as follows: 
 amoxicillin: 8µg/ml and 2µg/ml 
 ciprofloxacin: 1µg/ml and 0.25µg/ml  
 colistin: 2µg/ml and 0.5µg/ml 
These concentrations were chosen as they represent a one-fold and four-fold reduction compared 
to the susceptible breakpoint concentration for each agent, based on CLSI guidelines. For 
purposes of clarity, these will be referred to as the “high concentration” and “low concentration” 
exposures (Figure 4.1 a & b). 
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Figure 4.1a: Set-up for the “high concentration” antibiotic exposure experiment. Cf= Final 
Concentration, Amox= amoxicillin, Ert= ertapenem, Gent= gentamicin, Nal= nalidixic acid, 
Ctx= Cefotaxime, Col= colistin, Cip= ciprofloxacin 
 
 
 
Figure 4.1b: Set-up for the “low concentration” antibiotic exposure experiment. Cf= Final 
Concentration, Amox= amoxicillin, Ert= ertapenem, Gent= gentamicin, Nal= nalidixic acid, 
Ctx= Cefotaxime, Col= colistin, Cip= ciprofloxacin. 
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The sterile vials were incubated under aerobic conditions for 48 hours at 37˚C, following which a 
200 µl aliquot was spread onto the surface of a MacConkey agar plate with crystal violet (NHLS 
Media Laboratory, Greenpoint, South Africa) to suppress the growth of Gram-positive 
organisms, using a glass spreader. Antibiotic discs [amoxicillin (10 µg), ertapenem (10 µg), 
ciprofloxacin (5 µg), colistin (10 µg), cefotaxime (30 µg) and nalidixic acid (30 µg)] (Mast, 
Laboratories, UK) were added (Figure 4.1a & b), and three replicates were performed. The agar 
plates were incubated for 18-24 hours at 37°C. Isolates morphologically consistent with E. coli 
and K. pneumoniae growing inside the zones of inhibition of the various antibiotic discs were 
enumerated using a semi-quantitative approach. The following categories were used to describe 
the growth of Gram-negative bacilli around the antibiotic discs in the control (no antibiotic) 
sample (Figure 4.2): 
 No zone (growth completely up to the disc, no clear zone of inhibition) 
 Numerous (multiple discrete colonies up to the disc, but within a clear zone of inhibition) 
 Hazy, (indistinct – growth within an identifiable zone of inhibition, but no discrete 
colonies) 
 No growth (no colonies – clear zone of inhibition around the disc)  
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Figure 4.2: Categories used to describe growth around the antibiotic discs, A= Amoxicillin, E= 
Ertapenem, G= Gentamicin, CX= Cefotaxime, CT= Colistin, CP= Ciprofloxacin, N= Nalidixic 
Acid 
 
The samples exposed to antibiotic were compared to the control and results expressed relative to 
the control, for each antibiotic disc: 
1. Same as control (→) 
2. Less than control [fewer colonies around the disc compared to the control sample (↓)] 
3. More than control [more colonies around the disc compared to the control sample (↑)] 
4. No zone [only applicable if there had been a zone around the disc with the control (↑↑↑)] 
5. No growth [no growth of Gram-negative organisms around the disc (↓↓↓)] 
 
A single colony from around each disc (if present) was sub cultured on TBA plates (NHLS 
Media Laboratory, Greenpoint, South Africa) and incubated as previously described (chapter 2, 
section 2.2.4). Single isolates from the TBA plate were stored in microbank beads for further 
investigation. 
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4.3  Results 
The results after exposure to the high concentrations of antibiotics were similar to those after low 
concentration exposure, as summarized below.  
 
Amoxicillin  
There was no notable difference between the susceptibility profiles of isolates from samples after 
amoxicillin exposure compared to the no antibiotic control (NAC) (Table 4.1), apart from sample 
D002804J. This sample showed more growth around all of the antibiotic discs (except the 
quinolone and ertapenem discs) after exposure to both low and high concentrations of 
amoxicillin.  
 
Ciprofloxacin  
Exposure to ciprofloxacin selected for higher rates of resistance to quinolones in nine of the ten 
samples which were involved in this in-vitro pilot study. Eight out 10 samples which had isolates 
which were resistant to quinolones in NAC developed higher numbers of isolates resistant to 
quinolones and one sample (D003205H) where no quinolone resistant isolates were previously 
identified show selection of quinolone resistance (based on the semi-quantitative assessment of 
growth around the nalidixic acid and ciprofloxacin discs). A smaller number of samples exposed 
to ciprofloxacin showed increased rates of resistance to amoxicillin (2 samples) and gentamicin 
and cefotaxime (1 sample; 000805C – after exposure to the high ciprofloxacin concentration) 
(Table 4.2). 
 
Colistin  
Exposure to colistin selected for resistance around the amoxicillin disc in two samples. 
Decreased growth was also seen around the amoxicillin disc in two samples exposed to colistin. 
Growth around the quinolone and cefotaxime discs decreased in 7 and 2 samples respectively. 
However, in one of the samples (D003205H) growth around the colistin disc decreased after 
exposure to 2ug/mL of colistin and increased after exposure to 0.5 ug/mL of colistin.
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NAC=no antibiotic control, →Growth similar to NAC, ↑Increased growth compared to NAC, ↓less growth than NAC, ↑↑↑No Zone, ↓↓↓No Growth, NAC=no antibiotic control, Quinolones= nalidixic 
acid & ciprofloxacin, NG= No growth on plate. The first column shows the concentration of the antibiotic used. Antibiotics listed in the shaded horizontal rows refer to the antibiotic discs used. 
 
 
 
Table 4.1: Quantification of growth of isolates within the zone of inhibition of selected antibiotic discs after amoxicillin exposure.  
Amoxicillin Exposure 
Concentration D003205H D002804J D003206P D003302S D003502A D000706E D003802 D003402 D004002X D000805C 
 Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin 
NAC Numerous Numerous No Zone Hazy Growth No Zone No Zone No Zone No Zone Hazy Growth Hazy Growth 
8µg/ml → ↑↑↑ → → → → → → → → 
2µg/ml ↓ ↑↑↑ → → → → → → → → 
 Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones 
NAC No Growth Numerous Hazy Growth Numerous Hazy Growth Hazy Growth Numerous Numerous Hazy Growth Hazy Growth 
8µg/ml → ↓ → → → → → → → → 
2µg/ml → → → → → → → ↑ → → 
 Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin 
NAC No Growth No Growth No Growth No Growth Hazy Growth No Growth No Growth Numerous Hazy Growth Hazy Growth 
8µg/ml → ↑ → → → → → ↓ → → 
2µg/ml → ↑ → → → → → → → → 
 Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime 
NAC 1 Colony No Growth 1 Colony No Growth Hazy Growth No Growth No Growth Hazy Growth Hazy Growth Hazy Growth 
8µg/ml → ↑ → → → → → → → → 
2µg/ml ↑ ↑ → → → → → → → → 
 Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin 
NAC No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth 
8µg/ml ↑ ↑ → → → → → → → → 
2µg/ml → ↑ → → → → → → → → 
 Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem 
NAC No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth 
8µg/ml → → → → → → → → → → 
2µg/ml → → → → → → → → → → 
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Table 4.2: Quantification of growth of isolates within the zone of inhibition of selected antibiotic discs after ciprofloxacin exposure. 
Ciprofloxacin Exposures 
Concentration D003205H D002804J D003206P D003302S D003502A D000706E D003802 D003402 D004002X D000805C 
 Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin 
NAC Numerous Numerous No Zone Hazy Growth No Zone No Zone No Zone No Zone Hazy Growth Hazy Growth 
1µg/ml → NG → ↑↑↑ ↓ ↓↓↓ → → ↑↑↑ → 
0.25µg/ml → ↑↑↑ → ↑↑↑ ↓ ↓↓↓ → → ↑↑↑ → 
 Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones 
NAC No Growth Numerous Hazy Growth Numerous Hazy Growth Hazy Growth Numerous Numerous Hazy Growth Hazy Growth 
1µg/ml ↑↑↑ NG ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓ 
0.25µg/ml ↑↑↑ ↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ → ↑↑↑ ↑↑↑ → 
 Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin 
NAC No Growth No Growth No Growth No Growth Hazy Growth No Growth No Growth Numerous Hazy Growth Hazy Growth 
1µg/ml → NG → → ↓ → → ↓↓↓ → ↑↑↑ 
0.25µg/ml → → → → ↓ → → ↓↓↓ → → 
 Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime 
NAC 1 Colony No Growth 1 Colony No Growth Hazy Growth No Growth No Growth Hazy Growth Hazy Growth Hazy Growth 
1µg/ml → NG → → ↓ → → → → ↑↑↑ 
0.25µg/ml → → → → ↓ → → → → → 
 Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin 
NAC No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth 
1µg/ml → NG → → → → → → → → 
0.25µg/ml → → → → → → → → → → 
 Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem 
NAC No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth 
1µg/ml → NG → → → → → → → → 
0.25µg/ml → → → → → → → → → → 
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NAC=no antibiotic control, →Growth similar to NAC, ↑Increased growth compared to NAC, ↓less growth than NAC, ↑↑↑No Zone, ↓↓↓No Growth, NAC=no antibiotic control, Quinolones= nalidixic 
acid & ciprofloxacin, NG= No growth on plate. The first column shows the concentration of the antibiotic used. Antibiotics listed in the shaded horizontal rows refer to the antibiotic discs used. 
 
 
 
Table 4.3: Quantification of growth of isolates within the zone of inhibition of selected antibiotic discs after colistin exposure.  
Colistin Exposure 
Concentration D003205H D002804J D003206P D003302S D003502A D000706E D003802 D003402 D004002X D000805C 
 Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin Amoxicillin 
NAC Numerous Numerous No Zone Hazy Growth No Zone No Zone No Zone No Zone Hazy Growth Hazy Growth 
2µg/ml ↓ ↑↑↑ → ↓ → → → → ↑↑↑ → 
0.5µg/ml ↓ ↑↑↑ → → → → → → ↑↑↑ → 
 Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones Quinolones 
NAC No Growth Numerous Hazy Growth Numerous Hazy Growth Hazy Growth Numerous Numerous Hazy Growth Hazy Growth 
2µg/ml → ↓↓↓ ↓ ↓ ↓ ↓↓↓ ↓ ↓ → ↓ 
0.5µg/ml → → ↓↓↓ → ↓ → → → → → 
 Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin Gentamicin 
NAC No Growth No Growth No Growth No Growth Hazy Growth No Growth No Growth Numerous Hazy Growth Hazy Growth 
2µg/ml → → → → ↓ → → ↓ → → 
0.5µg/ml → → → → → → → → → → 
 Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime 
NAC 1 Colony No Growth 1 Colony No Growth Hazy Growth No Growth No Growth Hazy Growth Hazy Growth Hazy Growth 
2µg/ml → ↓ → → ↓ → → → → → 
0.5µg/ml → → → → → → → → → → 
 Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin Colistin 
NAC No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth No  Growth 
2µg/ml ↓ → → → → → → → → → 
0.5µg/ml ↑ → → → → → → → → → 
 Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem Ertapenem 
NAC No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth No Growth 
2µg/ml → → → → → → → → → → 
0.5µg/ml → → → → → → → → → → 
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4.4 Discussion 
The effect of varying (and sometimes sublethal) antibiotic concentrations on the selection of 
resistant bacteria is unclear (Gullberg et al., 2011). The gut flora of humans and animals are 
frequently exposed to a variety of concentrations of antibiotics due to their widespread use. In 
many instances, the concentrations in the gastrointestinal tract are sublethal and may select for 
resistance (Andersson & Hughes, 2014). This chapter set out to study the effects of low-level 
antibiotic exposure on the development of resistance in stool isolates, using a relatively simple 
in-vitro model. While the effects were modest, and no assessment was made of resistance 
mechanisms, there was some evidence that in a proportion of samples, greater numbers of 
resistant organisms were present after antibiotic exposure and notably, resistance to agents other 
than that to which the sample had been exposed. 
 
A previous study conducted by Kohanski et al, (2010) showed that when a wild-type E. coli was 
exposed to ampicillin (1µg/ml), the ampicillin MIC in the exposed isolates was 5-fold higher 
than the unexposed. In addition, isolates from the ampicillin exposure developed resistance to 
norfloxacin and kanamycin. However, in our study, the amoxicillin exposures did not select for 
higher levels of resistance except for one sample (D002804J), which is most likely because most 
of the isolates were resistant to amoxicillin prior to the exposures.  
 
In another study, E. coli isolates were exposed to sub-inhibitory concentrations of ciprofloxacin 
(0.1 x MIC) (Gullberg et al., 2011). This led to higher resistance, and even after several 
generations, E. coli isolates had a ciprofloxacin MIC that was 2-fold higher compared to wild-
type isolates. Similarly, in our in-vitro study, exposure to ciprofloxacin selected for high rates of 
resistance to ciprofloxacin. The only sample included in this pilot study which had no quinolone-
resistant isolates at baseline (D003205H), showed the presence of quinolone resistant isolates 
upon exposure to ciprofloxacin. Samples which had isolates resistant to only nalidixic acid in the 
no antibiotic control, upon exposure to ciprofloxacin yielded ciprofloxacin-resistant isolates as 
well. Although quinolone MICs were not determined, samples with isolates which were resistant 
to nalidixic acid and ciprofloxacin but with measurable zones around the discs, upon exposure to 
ciprofloxacin had no zones around the two discs, suggesting an increase in the MIC, or an 
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increase in the number of resistant isolates (or both). Our results are similar to those of an in vivo 
study, which showed the emergence of resistance when commensal bacteria were exposed to 
sub-MIC concentrations of ciprofloxacin (Fantin et al., 2009). Healthy adults were given a daily 
dose of ciprofloxacin (250 mg twice a day or 500 mg twice a day) and fecal samples were 
collected prior to treatment and on days 7, 14, and 42. The concentration of ciprofloxacin in the 
stool was determined using liquid chromatography, and ciprofloxacin was not detected in the 
stool at day 42. Resistance emerged in 25% of the participants mainly when the concentration of 
ciprofloxacin was sub MIC (Fantin et al., 2009). The emergence of resistance was however not 
significantly different across the different antibiotic dosages, which is similar to our findings 
where both concentrations of ciprofloxacin resulted in increased numbers of resistant isolates.  
 
Exposure to colistin demonstrates an irregular selection which could not be followed up. 
Analysis of our results is likely confounded by the poor performance of colistin discs on agar 
plates. For this reason, disc diffusion has not been approved for colistin susceptibility testing. 
Nine out of 10 samples showed no difference compared to the NAC around the colistin disc, and 
six out of 10 samples showed no difference between the growth around the various discs in the 
colistin exposures and the NAC. Four of the samples differed around other antibiotic discs, but 
this did not follow any specific pattern. 
 
However, when sample D002804J was exposed to 1 µg/ml of ciprofloxacin there was no growth 
on the plate. This could mean that the higher concentration of ciprofloxacin eliminated all the 
isolates in the sample. 
 
One other thing is to consider is whether sub-MIC antibiotic concentrations in the environment 
are able to select and enrich resistance as we have shown in our study. When patients are 
exposed to low doses of antibiotics for a long period of time, or animals are treated with low 
antibiotic concentrations to promote growth, a concentration gradient is built in the various 
compartments of the body; especially the intestines. These concentrations are likely to be at sub-
MIC levels which can select for resistance. The environment might be serving as a major 
reservoir because antibiotic use is not controlled in community settings, and in many countries 
(especially low- and middle-income countries) people can buy antibiotics over the counter. 
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These antibiotics may be of poor quality with reduced activity and combined with people either 
not completing the treatment course or taking doses erratically, may expose microorganisms to 
low-level antibiotic concentrations. Patients treated with antibiotics may excrete these into the 
sewage system, which is then discharged into water bodies in the environment. Fluoroquinolones 
are known to reach high levels in hospital sewage (Larsson et al., 2007; Lien et al., 2016; Picão 
et al., 2013).  
 
More quinolone resistant isolates were detected in the NAC than using the original baseline 
screening approach; and therefore, the baseline stools should be screened using multiple different 
antibiotic discs for the detection of isolates resistant to all classes of antibiotics. Another 
approach which can be used for screening for resistance is a direct/targeted metagenomics study, 
which could be considered for further studies. Direct/targeted metagenomics targets all 
organisms in a microbial community (resistome) and does not focus on a specific genus/family 
as we did in our study.  
 
The major limitation of the study is that the duration of exposure was short, and the 
quantification process was relatively crude. It is also important to note that the in-vitro study tries 
to simulate what happens in the gut, but we don’t know what role, if any, the interaction between 
the microbes in the stool samples plays in the development of resistance. 
 
We did not determine the MICs of the isolates at baseline and after exposure but with reference 
to the ciprofloxacin exposures we can say that sublethal antibiotic concentrations are likely to 
enrich and select for de novo resistance. The determination of MIC at baseline and after 
exposures is vital because it will provide the clinical significance of the sublethal antibiotic 
exposures. 
 
This approach worked in principle, nevertheless the in-vitro model is crude, and a more 
sophisticated model needs to be developed to understand the effect of in-vitro antibiotic 
exposure.  The use of a wider class of antibiotics should be considered for further studies since it 
will help understand the role of sublethal antibiotic concentrations in the selection of resistance.  
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 : General Discussion Chapter 5
Antibiotic resistance is a global challenge, especially in low- and middle-income countries. 
Various interventions have been proposed to help estimate the impact of antibiotic resistance, 
including public education, surveillance and understanding the epidemiology of resistance 
(WHO, 2014).  Not enough has been done in developing countries to implement policies to 
mitigate antibiotic resistance and control antibiotic usage (Laxminarayan & Heymann, 2012). 
However, for the past six years South Africa has implemented major policies to mitigate 
antibiotic consumption. This includes the establishment of the South African Antibiotic 
Stewardship program (Schellack et al., 2017). 
 
Antibiotic surveillance is needed to combat antibiotic resistance because it will provide the data 
required for the development of strategies and actions to mitigate antibiotic resistance (CDC, 
2013). For antibiotic surveillance to be effective, population-based surveillance needs to be 
encouraged (WHO, 2014). The TB-CHAMP trial provided an opportunity to obtain data on 
resistance rates in a community-based, pediatric population. We aimed to describe baseline rates 
of antibiotic resistance in Gram-negative bacilli (E. coli and Klebsiella spp.) in children in Cape 
Town and to investigate the effect of antibiotic exposure on the development of resistance in 
stool samples. 
 
Fifty participants were included in this study and 66% of them were colonized by isolates 
resistant to at least one antibiotic. More concerning was that 34% were colonized by MDR 
isolates. A single Klebsiella pneumoniae isolate was resistant to carbapenems which is 
unexpected in the community. Carbapenems are last resort antibiotics and the production of 
carbapenemases are a major cause of carbapenem resistance (Papp-Wallace et al., 2011). The 
carbapenem-resistant isolate harbored the NDM gene which is the most common carbapenemase 
gene reported in K. pneumoniae isolates in South Africa. To the best of our knowledge, this is 
the first study to show carriage of carbapenem resistant isolates in otherwise healthy children in a 
community setting in South Africa. Carbapenem-resistant Enterobacteriaceae (CRE) are an 
emerging health risk and further community surveillance needs to be done to better understand 
and estimate the prevalence of CRE in the community.   
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Resistance to third generation cephalosporins is a major indicator of ESBL production (Paterson 
& Bonomo, 2005), and 34% of the participants were colonized by ESBL-producing isolates 
based on PCR and sequencing. The only ESBL gene was CTX-M, which is the most common 
ESBL gene reported in community and nosocomial settings (Cantón & Coque, 2006). While 
genes such as SHV-1, SHV-11, and SHV-26 were also identified, these genes are considered 
non-ESBLs because they lack extended spectrum activity. The high rate of ESBL carriage in our 
study is concerning since these enzymes are plasmid-encoded and are likely to be transferred 
among different bacterial species. These enzymes are also a global threat because they confer 
resistance to the cephalosporin class of antimicrobials, which are commonly used agents 
worldwide. Global usage of antibiotics increased by 36% from 2000-2010  and in 2010 
cephalosporins and extended-spectrum penicillins accounted for 55% of the total antibiotics 
consumed (Van Boeckel et al., 2014) 
 
Quinolones are another commonly used class of antibiotics (Aldred et al., 2014). While 
resistance to quinolones has typically been associated with mutations in the gyrA and parC 
genes, plasmid-mediated quinolone resistance genes such as qnrA, qnrB and qnrS have also been 
associated with quinolone resistance. All isolates resistant to quinolones were subjected to PCR 
for the identification of plasmid-mediated quinolone resistance genes and for the detection of 
mutations in the gyrA and parC genes.  The most common quinolone resistance mechanisms in 
our isolates were mutations in the parC and gyrA genes, which are not transferable but lead to 
higher levels quinolone resistance. Mutations in gyrA or parC were detected in all isolates with 
quinolone resistance. Four out of 5 E. coli isolates harboring qnrS also had double mutations in 
gyrA and a single mutation in parC. K4 (the carbapenem-resistant isolate) was the only 
Klebsiella isolate with mutation in gyrA and a triple mutation in parC; all the others had double 
mutations in parC and no mutation in gyrA.  
 
The commonest plasmid-mediated quinolone resistance gene was qnrB in Klebsiella isolates and 
qnrS in E. coli isolates. Contradicting our findings, a study in healthy children in Peru and 
Bolivia revealed that the majority of E. coli carried qnrB while Klebsiella isolates carried qnrS 
(Chapter 1, section 1.5.1.2). However, the presence of one type of plasmid mediated quinolone 
resistance in E. coli and a different one in Klebsiella isolates is novel and unexplained. Our 
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findings reveal a high rate of quinolone-resistance in our isolates, raising the question of what 
might be driving the high prevalence of quinolone resistance in the community. All  mutations 
seen in quinolone-resistant E. coli and Klebsiella isolates have been commonly reported in 
literature to cause quinolone resistance (Nouri et al., 2016; Onseedaeng & Ratthawongjirakul, 
2016). MIC testing will help to understand how the number of mutations influences the selection 
of the appropriate dosage of quinolones.  
 
To study the acquisition of resistance, an in vitro model was employed. The stool samples were 
exposed to varying concentrations (low concentrations are potentially more likely to select for 
resistance) of amoxicillin, ciprofloxacin, and colistin. Although most of our samples had 
amoxicillin-resistant isolates at baseline, the only sample which had an amoxicillin-susceptible 
isolate develop amoxicillin resistance when exposed to amoxicillin. All samples exposed to 
ciprofloxacin either generated ciprofloxacin resistant isolates (if not detected previously) or 
increased the proportion of resistant isolates (if resistance present prior to ciprofloxacin 
exposure). This in itself may not be particularly surprising, as exposure to ciprofloxacin might be 
seen as a screening process to enhance the recovery of resistant isolates. However, further studies 
investigating the effect of low-level exposure on the spread of mobile elements and the rate of 
selection may provide important insights into the mechanisms driving resistance selection. The 
use of levofloxacin for MDR-TB prophylaxis in the TB-CHAMP project is likely to select for 
resistance based on what we have seen in our in vitro model. This may be aggravated by the fact 
that quinolones have a high recovery rate in stools (De Lastours et al., 2014). 
Colistin exposures did not select for higher resistance around the colistin discs but rather reduced 
the growth around the various antibiotic discs.  
 
The clonal relatedness of isolates in the stool of the participants was greatly diverse which made 
it difficult  to test the hypotheses related to the role of bacterial lineage on the development of 
resistance (Jayol et al., 2014). Future studies could focus on in-vitro exposure using different 
lineages, this might be a way to assess whether certain lineages acquire resistance more readily 
than others. 
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Our results suggest that resistant E. coli and Klebsiella spp are frequently carried in the stools of 
children in Cape Town communities and pose a risk to empiric treatment practices. This supports 
the speculation that resistance may reflect “spillover” from hospital settings. To confirm this 
speculation, further studies should be done by screening patients before admission and after 
discharge to determine whether they have acquired resistant isolate while hospitalised, which 
they might be carrying into the community. The presence of the plasmid-mediated genes is 
concerning and may result in increased quinolone and cephalosporin resistance. In conclusion, 
we suggest that a larger sample size and a metagenomic study should be employed in further 
studies to investigate the burden of antibiotic resistance carriage in the community. Recruiting a 
larger portion of the population will help understand the mode of trasmission of antibiotic 
resistance whiles the metagenomic study allows one to assess both cultured, uncultured bacteria 
and a broader range of resistance genes. It also helps in discovering novel resistance genes.  
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Appendices 
Appendix 1: Stool SOP TB-CHAMP Version 1_ 20190114 
 
DESMOND TUTU TB CENTRE (DTTC) 
STANDARD OPERATING PROCEDURE (SOP) 
Division:  
SOP Number:  
SOP Name: Study Specific stool collection aspects for TB CHAMP 
SOP version: Version 1.0 
SOP version date: 14 January 2019 
Training Implications: 
Principal Investigator ☒ Regulatory ☒ 
Sub-Investigator ☒ Data Personnel ☐ 
Study Coordinator ☒ Finance Personnel ☐ 
Pharmacist ☐ Receptionist/Admin personnel ☐ 
Study Nurse ☒ Driver ☒ 
Lab Personnel ☐ Cleaner ☐ 
Counsellor/Recruiter ☒ Other ☐ 
 
SOP Compiled By: Kristien Nel Van Zyl (Division Medical Microbiology, SU); 
Supervisor: Prof A Whitelaw 
SOP Approved by:  
____________________                        ______________________ 
Prof Anneke Hesseling                            Date        
 
FOR REGULATORY USE ONLY 
Distributed to: 
Site: Name & Surname: Signature: Date: 
Tygerberg    
Brooklyn Chest Hospital    
Ubunye    
Beautiful Gate    
Tambo Road    
Kuilsriver    
Data Office    
Lab Office    
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SOP Review and version management 
Review Dates Reviewed By Changes Required Version & Date 
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STANDARD OPERATING PROCEDURE (SOP) - Study Specific stool collection aspects 
for TB CHAMP. 
 
Objectives  
This SOP describes the procedure for collection of stool specimens for the purpose of bacterial 
culture and molecular microbiome studies, in the context of the TB-CHAMP study. 
 
Procedures  
 
 Equipment 
 
Table 1: Equipment required 
STOOL COLLECTION 
1 Sample container. Faecal Container (screwcap) With Spoon (25 ml) 
(LASEC product number: PLPS109047) 
2 Leak-proof bag 
3 Opaque carrier to protect dignity 
4 Cling-wrap (optional) 
5 Potty/Bed-pan (optional) 
TRANSPORT 
6 Labels and indelible marker pen  
7 Transport coolbox  
8 Icebrick 
9 Stool requisition form 
SAMPLE PROCESSING 
10 Cotton Swabs 
11 Cary Blair Medium 
12 DNA buffer (if used) or -80 freezer 
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 Stool collection 
 
1. Procedure for clinic collection 
1.1. Study nurse/ counsellor must collect stool as per DTTC stool collection SOP (PC011 
Stool Collection Version 1.0) 
1.2. Make sure no urine, water, soil or other material gets in the container. An attempt should 
be made to collect a specimen that consists primarily of stool when only a mixture of 
stool and urine is available. The stool should be mixed with the spoon at least five times 
to generate a homogeneous mixture. At least 6 scoops of stool needs to be added into the 
container. If the stool is loose, collect at least 3 scoops of watery stool (only if it is free 
from urine as stated above) and 3 of more solid stool. 
1.3. Ensure that the specimen containers are sealed well and disinfect the outside with 70% 
alcohol if necessary. The container should be placed in a sealable plastic bag. Label the 
collection container with the Subject Event barcode. 
1.4. The clinician / Study nurse / counsellor should complete the stool requisition form 
(DTTC TB-CHAMP Stool Requisition Form V1.2 
1.5. Keep specimen in the fridge (2-8°C) at the site and transport to Tygerberg Hospital in 
coolboxes on ice on the same day as collection, or as soon as possible. Avoid freezing 
the sample as subsequent thawing during transport may cause DNA degradation.  
2. Procedure for home collection 
2.1. Clear and simple verbal instructions regarding the method of stool collection should be 
given to the caregiver by the study nurse/ counsellor or counsellor, along with the 
instruction leaflet (TB-CHAMP_Parent Instruction Leaflet_V1.0).  
2.2. The caregiver should be given a stool container, leak-proof bag and opaque plastic box 
 In addition, if the caregiver has a freezer at home, a coolbox and icebrick should be 
provided. The icebrick must be kept in the freezer until required (see 2.4) 
2.3. Encourage the caregiver to put the stool sample in the collection container provided by 
the study team, and to note the time and date of stool collection - preferably taken as 
soon as possible before the clinic visit (night before, or ideally the morning of the clinic 
visit). 
2.4. Once collected, the sample should be kept on the icebrick in a coolbox (if provided), or 
in the coolest place in the home until delivered to clinic. 
 The study team must inform the caregivers that stool should not be collected on a 
Friday afternoon as the sample will only reach DTTC on the Monday. 
2.5. For baseline (BL) stool should be taken at screening visit, and if not obtained a sample 
collection kit will be provided for home collection. The kit and sample will then be 
returned at BL visit. 
Stellenbosch University https://scholar.sun.ac.za
83 
 
 In cases where screening and BL occur on the same day, the stool should 
preferably be collected before treatment/placebo is issued. If this is not possible, 
then the stool can be collected within 24 hours of the treatment/placebo. 
 For 8-, 16-, 24- and 48-week follow-up samples, if participants are unable to 
deliver a stool sample at the clinic, a sample collection kit will be provided to 
them for home collection. A driver will pick-up the samples from the home. Stool 
samples can be collected up to 2 weeks after the visit. 
 The study team should follow-up with the caregivers everyday after the visit until 
they can confirm that a sample was taken and collected. 
 No suppository should be given to the child for the purpose of the stool collection.  
 
Transport 
 
1. When a driver collects a stool sample (from clinic OR participant home), he / she should 
1.1. Have a cooler box and frozen ice brick ready for transporting stool samples 
1.2. Wear gloves, ensure that the collection container is sealed and disinfect the outside with 
70% alcohol if necessary 
1.3. Fill out the stool requisition form (if not completed by clinician / study nurse/ counsellor 
(1.4) and ensure the Subject Event barcode is pasted on the collection container. 
2. Preparation of specimen and transport to the Laboratory 
2.1. The specimen must be transported to the Division of Medical Microbiology (Room 561, 
9
th
 Floor, Green Lane East, Tygerberg Hospital) as soon as possible in a cooler box with 
an ice pack to keep it at 2-8°C during transport. 
2.2. If delivery to TBH is unsuccessful, the sample should be brought to the DTTC (Room 
0065, K-floor, Stellenbosch University Medical School) and stored at -80°C. This should 
also be noted in the comment section of the requisition form. 
2.3. A WhatsApp group called “TB-CHAMP Stool” will be created to enable communication 
between the Medical Microbiology laboratory team members, at least one member from 
the DTTC laboratory and the drivers. 
 
Lab Section Only: Sample processing 
 
1. Upon arrival at the Medical Microbiology laboratory, the stool requisition form will be 
signed by the recipient, noting the time and date of arrival. 
2. The sample will be split into two as soon as possible 
2.1. A swab or spoonful of stool is to be transferred to Cary Blair medium for culture work. 
2.2. A spoonful of stool is to be transferred to DNA stabilizing buffer (if used) 
2.3. The remainder of the sample will be frozen and stored at -80°C 
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2.4. A separate sample barcode will be created for each sample split as outlined above and 
placed on the requisition form. 
 
QC Process for Stool Requisition form 
 
The final QC of the stool requisition form will be performed by the Medical Microbiology TB-
CHAMP personnel. Should there be any missing fields or incorrect data on the stool requisition 
form, the Medical Microbiology TB CHAMP personnel will follow the below steps to rectify the 
error. 
 
a. Complete the Data Clarification Form (DCF) for stool Collected V1.0. Indicate 
PID and current data that needs to be rectified. 
b. Email the Data Clarification form to the site contact; 
i. Contact at Beautiful Gate: Andiswa Vavi:  bpvavi@sun.ac.za, 083 774 
2527 
ii. Tambo Road: Daphne van Ster: daphnev@sun.ac.za, 0834839075 
c. Site will complete and sign Data Clarification form and email the form back to the 
Medical Microbiology TB CHAMP staff.  
d. Medical Microbiology TB-CHAMP personnel will then be print and staple DCF 
to the original stool requisition form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University https://scholar.sun.ac.za
85 
 
 
 
STANDARD OPERATING PROCEDURE (SOP) 
SIGNATURE LOG 
Division:  
SOP Number:  
SOP Name: Study Specific stool collection aspects for TB CHAMP 
SOP version: Version 1.0 
SOP version date: 14 January 2019 
    
NAME SIGNATURE DATE 
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Appendix 2: DTTC TB-CHAMP Stool Requisition Form V1.2 20190206 
                                      DTTC    TB-CHAMP Clinical Trial 
                                         REQ1 – Stool Requisition Form 
 
Collection Date D D M M Y Y Y Y  Pick-up Date D D M M Y Y Y Y 
Collection Time H H H M M M    Pick-up Time H H H M M M   
         Drop-off Time H H H M M M   
Visit 
0 0_Baseline 
  
   
1 1_8 weeks 
Collection 
method 
1 1_Stool collected from diaper 
 
2 2_16 weeks   2 2_Stool collected from cling film over toilet 
 
3 3_24 weeks   3 3_Stool collected from potty/bedpan 
 
4 4_48 weeks    
 
        
 
Site 
1 Tambo Road   
Storage 
method 
1 1_Stool stored in fridge 
 
2 Beautiful Gate   2 2_Stool stored in coolbox with icebrick 
 
3 7th Floor Tygerberg   3 3_Stool stored without icebrick 
 
4 Home    
 
 5 Robert Gie Ikamva Wing    
 
      
 
Comment: 
  
 
 
FOLLOWING SECTION FOR LAB USE ONLY: STOOL SAMPLES ONLY 
 
Sample Barcode #1 Sample Barcode #2 (Culture) Sample Barcode #3 (Microbiome) 
 
      
 
  
 
 Stool Processed   Stool Processed   Stool Processed   
 
 Stool Stored   Stool Stored   Stool Stored   
 
     
 
Stool weight processed g Stool Appearance  Solid  Liquid 
 
Processed by:     Semi solid  Sticky 
 
Processed date: D D M M Y Y Y Y    
 
            
 
Comment (stools): 
    
 
     
 
FOLLOWING SECTION TO BE COMPLETED BY DRIVER/CLINICIAN AND TBH RECIPIENTS 
      
 Initial Date Signature 
Form Completed by:  D D M M Y Y Y Y  
Site QC completed by:  D D M M Y Y Y Y  
Lab QC completed by:  D D M M Y Y Y Y  
Form Captured by:  D D M M Y Y Y Y  
 
PID 
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Appendix 3: TB-CHAMP_Caregiver Instruction Leaflet Nappies_20180528 
 
GOAL: We look at stool to find out how germs in the gut are changed by the medicine. This will 
help us decide about using this medicine in future. 
 
Tips for collecting a stool sample from toilet-trained children 
 Many older children do not like to give a sample of their stool for testing. Talk to your 
child using simple, honest words. Show them you understand by saying something like “I 
know this may be embarrassing for you, but we need to do this because…” This will 
allow your child to express their feelings and accept your help. 
 When taking the stool sample, make sure that the sample does not fall into the toilet.  
 If the stool falls into the toilet water or is mixed with urine, do not collect it.  
 Watch your child if they are young and might not understand that their urine must be kept 
separate from the stool being collected.  
You can collect the stool like in option 1 (below) or option 2 (on back of page): 
Option 1: You can collect a stool sample by stretching plastic wrap/sheet over the toilet 
A. Lift the toilet seat 
 
 
 
 
 
 
B. Cover the toilet bowl with plastic sheet  C. Lower toilet seat over the plastic 
Follow these steps:  
a. First have your child pass urine into the toilet, without pooping.  
b. Lift the toilet seat and cover the entire bowl with a large sheet of plastic. If the plastic sheet 
does not stick to the toilet, you may need to use tape to stick it down.  
c. Make a small dip in the middle of the plastic so there is a place for the stool to collect.  
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d. Lower the toilet seat cover and have your child poop onto the plastic sheet.  
e. Using the scoop or the small white spoon given to you, transfer the last part of the stool into 
the collection container given to you. Collect at least 6 scoops into the container. Follow the 
steps on the next page. 
 
Option 2; You can collect a stool sample using a potty.  
Follow these steps: 
a. Let the child first pass urine into the toilet.  
b. Then have the child sit on the potty and pass stool.  
c. Using the scoop or the small white spoon given to you, transfer the last part of the stool into 
the collection container given to you. Collect at least 6 scoops into the container and fill it up 
to the mark. Follow the method shown below.  
Steps for collecting stool from the plastic sheet or potty into the container: 
 
1. Use the container 
provided 
 
 
 
 
 
 
 
 
 
2. Unscrew the cap. 
Mix the stool 5 
times 
 
 
3. Scoop 6 spoons of 
stool from the 
plastic or potty 
4. Put the stool into 
the container 
x5 
x6 
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5. Screw the cap 
tightly closed. 
Write down the 
date and time on 
the label on the 
container 
 
 
 
 
 
 
 
 
 
6.  Put the container 
inside the plastic 
bag provided and 
seal the bag 
7. Wash hands very 
well with soap and 
water 
 
8. If you are at the 
clinic let the 
study nurse know 
as soon as 
possible that you 
have collected the 
stool sample 
 
9. If you are at 
home, put the bag 
with the container 
in the box 
provided and 
keep in the 
coolest place in 
your home (like a 
fridge) 
10. If you were 
provided with a 
cooler box and ice 
brick, put the 
lunchbox in the 
cooler box on the 
frozen icebrick 
when you bring it 
to the clinic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE: 
 If the stool is watery, try not to let the 
stool run off the plastic. 
 Collect at least 3 scoops of watery 
stool and 3 of more solid stool. 
 If it is all watery, collect 6 scoops of 
watery stool. 
 It is important that no urine or toilet 
water mix with the stool sample. 
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Appendix 4: Biomarkers 
 
Figure 5: DirectLoad™ Wide Range DNA Marker (Sigma, Aldrich, Germany) 
 
 
Figure 6: New Biolabs 100bp Ladder (New England Biolabs Inc.). 
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